roche annual report finance report part innovate healthcarewe innovate healthcare researchintensive healthcare company roche discovers develops provides innovative diagnostic therapeutic products deliver significant benefits patients healthcare professionals early detection prevention diseases diagnosis treatment treatment monitoring longterm strategic focus roche strives deliver sustainable value stakeholderstable contents finance report roche group finance brief finance brief financial review operating results nonoperating results cash flows net cash balance sheet pensions postemployment benefits roche securities financial risks international financial reporting standards roche group consolidated financial statements income statement balance sheet cash flow statement statement recognised income expense statement changes equity notes roche group consolidated financial statements report roche management internal control financial reporting report group auditors report group auditors internal control financial reporting multiyear overview supplementary net income eps information roche securities roche holding ltd basel financial statements income statement balance sheet notes financial statements appropriation available earnings report statutory auditors finance report finance brief key results operating profit margin local sales growth sales pharmaceuticals diagnostics group change sales mchf mchf chf lc sales research development ebitda operating profit net income core eps chf dividend per sharein chf december december change chf net cash equity equity ratio ebitda earnings financial income financing costs tax depreciation amortisation including impairment corresponds operating profit depreciation amortisation including impairment see definition core eps proposed board directors lc local currencies finance executive committee erich hunziker chief financial officer hubert buck management development peter eisenring taxes insurances marco frei pension asset management andreas knierzinger treasury steve krognes corporate development karl mahler investor relations erwin schneider accounting controlling finance report finance brief sales group sales grew local currencies billion swiss francs driven primarily fast organic growth pharmaceuticals division pharmaceuticals sales increased local currencies billion swiss francs strongly outperforming global market growth thanks key oncology products also bonvivaboniva lucentis pharmaceuticals sales account group sales oncology product sales grew local currencies billion swiss francs representing pharmaceuticals sales diagnostics sales increased local currencies billion swiss francs driven primarily professional diagnostics business operating results operating profit increased local currencies billion swiss francs based strong business growth continuing productivity improvements record profitability operating profit margin percentage points rd expenditure increased local currencies billion swiss francs representing group sales significant investment acquisitions inlicensing merger agreement signed ventana medical systems january treasury net financial income stable million swiss francs compared million swiss francs repayment million us dollars bonds european medium term note programme retirement million us dollars lyons v convertible notes genentech establishes billion us dollar commercial paper program billion us dollars billion swiss francs utilised end financial condition increase net cash billion swiss francs billion swiss francs increase equity ratio decrease debtequity ratio aa rating moodys aa rating standard poors maintained net income core eps increase net income billion swiss francs primarily strong operating performance increase core eps swiss francs outpacing swiss franc sales growth percentage points shareholder return roches market capitalisation decreased billion swiss francs share price price nonvoting equity security broadly line european pharmaceuticals stock market increase proposed dividend swiss francs representing st consecutive year dividend growth approved shareholders result payout ratio dividend yield roche share nonvoting equity security based yearend prices finance report roche group financial review operating results group operating results sales operating profit exceptional items billions chf lc growth billions chf sales results show continuing strong operating performance sales operating profit margin level main impetus coming pharmaceuticals division total sales grew local currencies swiss francs us dollars billion swiss francs pharmaceuticals division representing group sales diagnostics division contributing incremental sales increase billion swiss francs achieved organic growth demand groups oncology drugs avastin herceptin mabtherarituxan tarceva xeloda continued strong additional growth drivers pharmaceuticals division ophthalmology drug lucentis bonvivaboniva metabolismbone cellcept transplantation pegasys virology diagnostics division growth areas professional diagnostics diabetes care applied science groups operating profit increased local currencies billion swiss francs corresponding operating profit margin grew percentage points driven increase pharmaceuticals percentage points percentage point increase diagnostics margin growth achieved time group continued increase investments launch prelaunch activities particular strong development pipeline increase diagnostics margin driven sales growth release accruals following bioveris acquisition positive effect absence intangible asset impairment charges exchange rate impact sales operating profit growth expressed swiss francs moderate swissfranc sales growth equal localcurrency growth swissfranc operating profit growth around percentage point higher average exchange rate euro higher thecomparative period us dollar lower japanese yen lost around group operating results pharmaceuticals diagnostics corporate group mchf mchf mchf mchf sales operating profit margin sales ebitda margin sales finance report roche group financial review group operating results development results compared pharmaceuticals diagnostics corporate group sales increase local currencies operating profit increase local currencies margin percentage point increase ebitda increase local currencies margin percentage point increase pharmaceuticals operating results pharmaceuticals division increased sales local currencies swiss francs us dollars billion swiss francs approximately twice global market growth rate operating profit billion swiss francs representing growth local currencies corresponding margin increased percentage points increase marketing costs significantly less growth sales due continued productivity improvements increase reflects support costs growing oncology portfolio broader indications particularly avastin well investments launch bonvivaboniva lucentis mircera relaunch tamiflu seasonal use growth research development expenses exceeded increase sales driven significant investments strong pipeline reflecting expanded portfolio largenumber clinical trials information divisional business pipeline see business report pages pharmaceuticals division results change change mchf mchf chf local currencies sales royalties operating income cost sales marketing distribution research development general administration operating profit margin sales ebitda margin sales salessales divisions oncology portfolio grew account pharmaceutical sales excluding supportive care products combined sales cancer therapeutics rose increasing roche groups share global market cancer medicines therapeutic areas also performed strongly notably metabolismbone inflammationautoimmunetransplantation two key pillars growth roche finance report roche group financial review pharmaceuticals division sales therapeutic area sales change therapeutic area mchf sales local currencies oncology inflammationautoimmunetransplantation virology metabolismbone renal anemia others total excluding tamiflu pandemic government corporate sales divisions top products representing pharmaceuticals portfolio grew products recording strong sales growth main sales growth pharmaceuticals division driven following key products avastin herceptin mabtherarituxan lucentis bonvivaboniva tarceva xeloda cellcept pegasys together products accounted total sales generated additional billion swiss francs sales revenue compared six top products tamiflu neorecormonepogin kytril xenical nutropin rocephin recorded sales decreases peak pandemic stockpiling sales billion swiss francs governmental andcorporate uptake tamiflu slowed expected sales billion swiss francs decrease product sales renal anemia particular due significantly lower epogin revenue japan reflecting ongoing impact governmentmandated price cuts reimbursement changes following patent expiry competitor product united states kytril sales decreased decline intheother products category resulted primarily generic erosion reduced sales viracept following therecall announced june pharmaceuticals division sales top products change sales local product mchf sales currencies franchise mabtherarituxan oncologyiat herceptin oncology avastin oncology neorecormonepogin renal anemia oncology tamiflu virology pandemic virology cellcept iat pegasys virology xeloda oncology tarceva oncology lucentis ophthalmology bonvivaboniva metabolismbone xenical metabolismbone xolair respiratory diseases valcytecymevene virology pulmozyme respiratory diseases nutropin metabolismbone kytril oncology neutrogin oncology rocephin infectious diseases activasetnkase cardiovascular diseases total top products products total finance report roche group financial review change sales local product mchf sales currencies franchise excluding tamiflu pandemic government corporate sales total top products products total inflammationautoimmunetransplantation mabtherarituxan doubledigit sales growth driven increasing use oncology indications rheumatoid arthritis europe us oncology sales growth due increasing usage mabtherarituxan following firstline therapy indolent nonhodgkins lymphoma nhl including maintenance use already high penetration rates firstline treatment indolent aggressive nhl sustained us europes five largest markets france germany italy spain united kingdom increasing adoption settings seen emerging markets adoption rheumatoid arthritis continued increase us europerow herceptin growth continued driven increasing adoption adjuvant early stage herpositive breast cancer roche estimates end products market share adjuvant setting approximately versus year earlier five largest european markets elsewhere market penetration setting also continues build us penetration market flattened due earlier rapid adoption herceptin adjuvant treatment metastatic setting adoption rates treatment duration remained stable us top five european markets avastin sales increased worldwide compared strong growth regions particularly europerow us growth driven primarily increased usage advanced nonsmall cell lung cancer nsclc indication approved late europe sales growth propelled uptake product metastatic colorectal cancer setting avastin received eu approval metastatic breast cancer march firstline treatment patients nsclc august initial uptake new indications encouraging avastin approved launched japan treatment metastatic colorectal cancer neorecormonepogin combined sales roches neorecormon chugais epogin epoetin beta market remains highly competitive due pricing pressure branded competitors entry biosimilar versions epoetin alfa europe decline neorecormon sales salesofepogin japan affected competitive pricing pressures first quarter residual impact governmentmandated price cuts reimbursement changes tamiflu sales tamiflu declined million swiss francs versus seasonal sales million swiss francs lower pandemic sales decreased million swiss francs compared stockpiling programmes governments corporations completed seasonal sales tamiflu japan negatively affected mild flu season outweighed however substantial increase pandemic sales japanese government cellceptthe immunosuppressant cellcept continued record steady sales growth worldwide driven solid demand us europe growth continues driven physicians recognition longterm protective benefits cellcept transplant patients compared toxic therapeutic options pegasys market share pegasys remains global market leader treatment hepatitis c sales driven increased use europerow offsetting decline us overall market volume decline market response positive japan following rollout combined pegasys plus copegus hepatitis c finance report roche group financial review xelodathe main contributions doubledigit growth xeloda came us europerow sales growth driven increased usage xeloda adjuvant colon metastatic colorectal cancer settings well european launch gastric cancer tarcevatarceva recorded strong growth particularly europerow sales region accounts overall sales us sales increased competitive market environment tarceva still epidermal growth factor receptor inhibitor proven survival benefit advanced lung pancreatic cancer lucentisfollowing us approval june lucentis experienced rapid uptake driven high demandfor treatment neovascular wet agerelated macular degeneration wet amd lucentis sales usgrew however year sales growth flattened medicine captured significant market share offlabel usage unapproved therapy wet amd remained high outside us lucentis ismarketed novartis bonvivabonivain highly competitive market sales bonvivaboniva ibandronic acid treatment postmenopausal osteoporosis increased million swiss francs million swiss francs compared majority sales come us products market share total prescriptions increased around bonviva gained reimbursement status launched many european markets xenicalsales prescription weightloss medication xenical orlistat mg declined worldwide united states roches partner glaxosmithkline successfully launched nonprescription orlistat mg brand name alli licensor roche receives royalties sales alli see business report part annual report information roches pharmaceutical products pages including rd pipeline sales regionsales continued grow across regions particularly north america europe emerging markets north american sales grew almost three times market rate driven products marketed genentech roche continued gain market share europe rest world driven strongsales growth herceptin avastin mabtherarituxan tarceva pegasys bonvivaboniva pharmaceuticals division sales region sales change region mchf sales local currencies north america europe japan latin america regions total royalties operating income increase million swiss francs local currencies mainly due high outlicensing income royalty income increased million swiss francs local currencies driven income novartis lucentis amgen enbrel gsk alli increase million swiss francs income outlicensing orlistat otc rights glaxosmithkline gsk genentech generated additional million swiss francs outlicensing income including million swiss francs recorded part new thirdparty collaboration agreement million swiss francs milestone income relating lucentis approval european union filing japan chugai million swiss francs additional thirdparty royalties operating income including milestone income codevelopment comarketing agreement taisho bonviva gains product divestments also significantly higher compared include gain million swiss francs disposal several cardiovascular products gain million swiss francs first stage thedisposal three products actavis part continuous realignment product portfolio royalties operating income percentage sales increased percentage points finance report roche group financial review royalties operating income change mchf mchf local currencies royalty income income outlicensing agreements income disposal products total cost salesthe increase local currencies increase sales growth royalty expenses product sales driven success mabtherarituxan herceptin tarceva cellcept lucentis avastin partially offset lower expenses tamiflu neorecormon viracept genentechs collaboration profitsharing expenses partners biogen idec novartis osi increased million swiss francs million swiss francs due increased sales mabtherarituxan xolair tarceva respectively additionally gross profit share glaxosmithkline increased million swiss francs million swiss francs following increased bonvivaboniva sales factors largely compen sated manufacturing efficiencies product mix effects despite million swiss francs costs viracept recall amortisation intangible assets remained stable percentage sales cost salesdecreased cost sales change mchf mchf local currencies manufacturing cost goods sold period costs royalty expenses collaboration profitsharing agreements amortisation intangible assets impairment property plant equipment impairment intangible assets total marketing distribution increase local currencies significantly sales growth due continued productivity improvements major activities included support strong oncology portfolio notably avastin lung breast cancer indications well tarceva pancreatic cancer europe main areas focus pegasys bonvivaboniva addition prelaunch launch costs mircera japan sales force significantly increased preparation launches avastin tarceva actemra addition tamiflus use seasonal flu pandemic planning beenfurther promoted marketing distribution costs percentage sales research development increase billion swiss francs local currencies almost billion swiss francs reflects higher spending result increased portfolio size large number latestage clinical trials significant work took place latestage projects driven many potential line extensions especially avastin oncology mabtherarituxan actemra rheumatoid arthritis research development costs percentage sales compared addition thepharmaceuticals division total spent million swiss francs capitalised assets pipeline compounds technologies inlicensing total division spent billion swiss francs internal purchased rd inlicensing deals representing sales finance report roche group financial review investments research development change mchf mchf local currencies research development expenses less noncash items amortisation intangible assets impairment intangible assets research development expenses excluding noncash items product intangibles available use technology intangibles research development related capital expenditure total investments research development general administration overall increase million swiss francs local currencies dueto variety factors administration costs grew include project harmonise business processes sap systems across europe well establish european shared services centre budapest legal expenses also included administration costs substantially higher compared excluding items administration costs increased addition restructuring expenses significantly higher primarily result reduction sales forces us europe general administration expenses percentage sales increased general administration change mchf mchf local currencies administration legal environmental settlements restructuring expenses gains losses disposal property plant equipment general items total pharmaceuticals subdivisional results operating operating sales ebitda ebitda profit profit mchf mchf sales mchf sales roche pharmaceuticals genentech chugai elimination within division pharmaceuticals division roche pharmaceuticals genentech chugai elimination within division pharmaceuticals division unrealised internal profits inventories sold one subdivision another yet sold external customers balance sheet date eliminated consolidation entry finance report roche group financial review roche pharmaceuticals sales increased strongly local currencies operating profit margin increased percentage points spite significantly higher research development expenses positive developments include increased income outlicensing product disposals lower marketing distribution cost ratio compensated higher expenses alliance collaboration partners include royalty expenses third parties billion swiss francs genentech billion swiss francs well profit sharing arrangements also higher general administration costs moreover roche pharmaceuticals continued significantly increase investments research development costs around million swiss francs sales returns inventory provisions costs recorded following recall viracept announced june genentech sales grew local currency operating profit margin significantly improved percentage points mainly driven substantially higher royalty operating income third parties royalty income roche pharmaceuticals also growth marketing distribution expenses considerably sales growth compensating strong increase investments rd chugaisales increased local currencies slightly market growth japan chugais sales excluding tamiflu pandemic rose local currencies operating profit chugai increased local currency due outlicensing income third parties roche pharmaceuticals offsetting unfavourable product mix impact driven increased share tamiflu government pandemic sales swiss franc terms resulted increase percentage points operating profit margin additional information pharmaceuticals divisions subdivisional results given note consolidated financial statements information genentech chugai given notes diagnostics operating results roches diagnostics division remained global leader vitrodiagnostics market market share around divisional sales increased billion swiss francs growing local currencies swiss francs us dollars compared operating profit increased local currencies billion swiss francs operating profit margin improved percentage points cash generation business remains well industry average ebitda margin operating profit margin improvement driven sales growth positively impacted reversal royalty accruals following acquisition bioveris absence significant impairment charges onintangible assets recorded second half factors compensated continued investments new existing products considerably higher general administration costs mainly due increased provisions legal environmental settlements postacquisition restructuring expenses bioveris division completed acquisition bioveris life sciences nimblegen total consideration billion swiss francs january group signed agreement acquire ventana medical systems approximately billion us dollars transaction expected completed first half information divisional business pipeline see business report pages finance report roche group financial review diagnostics division results change change mchf mchf chf local currencies sales royalties operating income cost sales marketing distribution research development general administration operating profit margin sales ebitda margin sales sales professional diagnostics diabetes care applied science businesses growth drivers biggest contributions coming immunochemistry blood glucose monitoring dna sequencing products respectively molecular diagnostics continued affected declining sales industrial reagents due expiration roches foundational pcr patents excluding part business molecular diagnostics sales grew diagnostics division sales business area sales change business area mchf sales local currencies professional diagnostics diabetes care molecular diagnostics applied science total professional diagnosticsroche professional diagnostics gained market share sales increased local currencies billion swiss francs immunochemistry sales rose local currencies billion swiss francs outpacing market seventh consecutive year growth fuelled demand elecsys ntprobnp troponin cardiac tests assay tsh thyroidstimulating hormone new tests launched second half vitamin osteoporosis mpa therapeutic monitoring cellcept mycophenolic acid therapies transplant recipients expected contribute future growth clinical chemistry business grew despite highly competitive costsensitive market demand cobas analyser series mediumworkload laboratories remained strong introduced series first several modular platforms designed integrate improve efficiency clinical chemistry immunochemistry testing different sized laboratories cobas e immunochemistry analyser first cobas instruments small mediumsize laboratories released first half year cobas c clinical chemistry analyser track launch acquisition bioveris completed june enabling roche expand immunochemistry business new market segments life science research drug development clinical trials also june roche sysmex corporation japan signed tenyear extension agreement giving roche exclusive distribution rights sysmex hematology instruments markets europe latin america southern africa oceania november roche signed licensing agreement orthoclinical diagnostics inc novartis vaccines diagnostics giving roche access broad portfolio hepatitis c virus hcv patents strengthening immunochemistry menu finance report roche group financial review sales pointofcare poc diagnostics previously near patient testing rose local currencies million swiss francs helped improved marketing business areas broad portfolio continued move towards decentralised testing coagulation monitoring sales increased driven coaguchek xs monitor patient use coaguchek xs plus monitor healthcare professionals systems released us japan first half sales poc cardiac markers accelerated following launch cobas h portable cardiac testing system february ambulatory care arena launch november accutrend plus expected boost growth first handheld instrument capable measuring cholesterol triglyceride glucose lactate levels blood using asingle meter diabetes care roche diabetes care remained global market leader sales billion swiss francs anincrease local currencies accuchek aviva accuchek compact blood glucose systems sold well compensating lower sales older accuchek advantage accuchek active sales especially strong emea south american markets roches insulin delivery business grew local currencies driven primarily european north american markets us market uptake accuchek spirit insulin pump positive business introduced two new glucose systems accuchek performa automatically corrects environmental factors affect test results andthe new allinone accuchek compact meter lancing device launched fourth quarter germany uk norway accuchek software package helps people diabetes healthcare professionals store access review detailed health information quickly conveniently also added tothe portfolio rollout three new products continue molecular diagnostics roche molecular diagnostics remained clear leader market increasing number players sales billion swiss francs overall decline local currencies excluding industrial reagent sales markedly declined expected growth sales virology products grew local currencies driven continued placements automated cobas ampliprepcobas taqman capctm platform europe asiapacific rollout platform us japanese markets second half blood screening sales decreased local currencies uptake cobas modular blood screening system remained strong europe sites adopted system cobas taqscreen mpx multiplex test simultaneously detects hiv hcv hbv donated blood plasma since european rollout roche introduced cobas system us west nile virus test second half notable contracts include threeyear deal supply automated capctm hiv test labcorp us fiveyear contract japanese red cross jrc fully automated integrated cobas system cobas taqscreen mpx multiplex test used screen jrcs roughly five million annual blood donations applied science roche applied sciences sales grew well ahead market rising local currencies million swiss francs main growth drivers lightcycler system highthroughput realtime pcr genome sequencer systems dna sequencing research reagents business area gained significant market share fastgrowing sequencing area retained share genomics systems market marketing nimblegen arrays started roches name integration nimblegen life sciences business area progressing planned roche doubled share rapidly expanding market dna sequencing products sales regions sales continued grow ahead line market regions regions contributed growth sales advancing doubledigit rates latin america asiapacific singledigit rates europe north america japan sales asiapacific grew almost twice fast market finance report roche group financial review diagnostics division sales region sales change region mchf sales local currencies emea north america asiapacific latin america japan regions total europe middle east africa royalties operating income income million swiss francs higher local currencies despite expiration foundational pcr patents countries outside us march royalties operating income percentage sales decreased percentage points royalties operating income change mchf mchf local currencies royalty income income outlicensing agreements income disposal products total cost sales overall decrease local currencies manufacturing cost goods sold period costs increased slightly sales royalty expenses decreased considerably local currencies million swiss francs primarily due reversal first half million swiss francs bioveris royalty accruals second half bioveris royalty accruals million swiss francs booked excluding bioveris royalty expenses million swiss francs increase local currencies line increase sales furthermore cost sales included impairment charge intangible assets million swiss francs percentage sales cost sales decreased excluding bioveris royalties impairment intangibles stable years cost sales change mchf mchf local currencies manufacturing cost goods sold period costs royalty expenses collaboration profitsharing agreements amortisation product intangibles impairment property plant equipment impairment product intangibles total marketing distributionthe increase local currencies higher increase sales mainly due strong investments new product launches cobas gene sequencing gs flx several initiatives support grow market share especially professional diagnostics diabetes care marketing distribution percentage sales increased comparative period research development costs increased local currencies comparative period included amillion swiss francs impairment charge intangible assets excluding impairment charge rd growth local currencies reflecting impact recent acquisitions investments rd projects research development expenses percentage sales increased excluding impairment charge finance report roche group financial review investments research development change mchf mchf local currencies research development expenses less noncash items amortisation intangible assets impairment intangible assets research development expenses excluding noncash items general administration general administration costs increased local currencies mainly driven increased provisions legal environmental settlements results included income settlement agreements also within general items postacquisition restructuring expenses bioveris million swiss francs growth administration costs compared sales growth general administration expenses percentage sales increased comparative period general administration change mchf mchf local currencies administration legal environmental settlements restructuring expenses gains losses disposal property plant equipment general items total corporate operating costs general administration costs lower local currencies million swiss francs million swiss francs foreign exchange impact operating results groups exposure movements foreign currencies affecting operating results expressed swiss francs summarised following key figures comments growth change change local currencies chf sales operating profit exchange rates swiss franc december average december average usd eur jpy finance report roche group financial review us dollar japanese yen weakened swiss franc euro many economies currencies appreciated swiss franc overall almost difference sales growth operating profit growth expressed swiss francs local currencies absolute terms sensitivity group sales movement us dollar swiss franc swiss francs approximately million swiss francs corresponding sensitivities euro yen approximately million swiss francs million swiss francs respectively sensitivities group operating profit approximately million swiss francs respectively nonoperating results nonoperating results change mchf mchf chf operating profit associated companies financial income financing costs profit taxes income taxes profit continuing businesses profit discontinued businesses net income attributable roche shareholders minority interests groups treasury operations delivered positive net financial income net income financial assets foreign exchange management exceeding financing costs million swiss francs groups effective tax rate declined despite increased pretax profit contribution genentech net income increased due combination positive developments operating taxlines net financial income millions chf financing costs financial income net financial income financial income financial income million swiss francs declining compared interest income income debt securities million swiss francs due higher holdings increases interest rates result improved despite writedown debt securities million swiss francs zero net income equity securities million swiss francs compared million swiss francs funds continue invested conservative risk profile expected returns pension plan assets million swiss francs compared net foreign exchange losses million swiss francs compared losses million swiss francs driven losses cash flow hedge contracts suffered strong appreciation currencies swiss franc full analysis financial income given note consolidated financial statements finance report roche group financial review financing costsfinancing costs million swiss francs basically stable compared increase interest rates small impact financing costs outstanding debt fixed interest rates amortisation debt discounts million swiss francs lower following redemption lyons v notes gain favourable market value movements debt instruments designated fairvalue throughprofitorloss million swiss francs million swiss francs full analysis financing costs given note consolidated financial statements income taxes groups effective tax rate declined compared rate increasing pretax profit contribution genentech acted increase overall group tax rate however offset fall effective tax rate genentech excluding genentech chugai underlying effective tax rate considerably lower equivalent rate reflects groups ongoing efforts optimise tax structure relatively lower profits hightax jurisdictions also onetime effects reduction corporate tax rates germany effective corresponding reduction deferred tax balance sheet positions information groupsincome taxes given note consolidated financial statements analysis groups effective tax rate profit income profit income tax taxes tax rate tax taxes tax rate mchf mchf mchf mchf roche excl genentech chugai genentech chugai groups effective tax rate discontinued businesses discontinued operations comparative results show small release longer required provisions finalisation divestments vitamins otc businesses information given note consolidated financial statements net income billions chf core eps chf net income group net income increased billion swiss francs net income attributable roche shareholders higher net income attributable minorities increased higher increase minority interests due increased contribution genentech total billion swiss francs minority interests billion swiss francs attributable genentech minority interests billion swiss francs chugai minority interests diluted eps chf chf change group core earnings per share increase diluted eps due increase net income attributable roche shareholders described core eps excludes amortisation impairment intangible assets increased supplementary net income eps information given page includes calculations core eps reconciles groups published ifrs results finance report roche group financial review cash flows net cash cash flows operating activities net cash income taxes billions chf billions chf condensed cash flow statement mchf mchf cash generated operations increase decrease working capital operating cash flows operating activities income taxes income taxes paid activities operating activities investing activities financing activities net effect currency translation cash increase decrease cash full consolidated cash flow statement given consolidated financial statements operating cash flowsthe groups business operations continued show strong cash generation billion swiss francs driven continued growth ebitda development business led increase working capital mainly inventories trade receivables payments income taxes higher billion swiss francs billion swiss francs relate genentech remaining billion swiss francs represent tax payments increased taxable profits also include payment previously accrued amounts relating final settlement german tax authorities number years including overall cash flows operating activities increased billion swiss francs investing cash flows largest investing cash flows expenditure property plant equipment billion swiss francs investing cash flows also include payments made acquisitions billion swiss francs driven billion swiss francs consideration bioveris billion swiss francs net cash cost tanox net cash outflow purchases sales marketable securities billion swiss francs financing cash flows significant financing cash flows relate dividend payments redemption debt instruments dividends paid billion swiss francs billion swissfrancs cash used retirement debt instruments billion swiss francs billion swiss francs genentech issued commercial paper resulting cash inflow billion swiss francs following retirement lyons v exchangeable notes group reduced equity instruments holdings realising net cash inflow billion swiss francs billion swiss francs genentech received billion swiss francs stock option exercises time genentech chugai repurchased shares total billion swiss francs finance report roche group financial review net cash december december mchf mchf change cash cash equivalents marketable securities longterm debt shortterm debt net cash net cash increased billion swiss francs cash inflow operating activities billion swiss francs used dividend payments billion swiss francs also capital expenditure included acquisitions primarily bioveris tanox purchases property plant equipment andintangible assets totalled billion swiss francs genentech chugai share repurchases reduced net cash billion swiss francs partly offset billion swiss francs received exercise employee stock options balance sheet balance sheet billions chf liabilities assets net assets equity condensed balance sheet december december mchf mchf change property plant equipment goodwill intangible assets noncurrent assets cash marketable securities current assets total assets debt current noncurrent noncurrent liabilities current liabilities total liabilities total net assets capital reserves attributable roche shareholders equity attributable minority interests total equity full consolidated balance sheet given consolidated financial statements finance report roche group financial review noncurrent assets fall us dollar swiss franc december compared end decreased longterm assets swiss franc terms many groups production facilities intangible assets denominated us dollars property plant equipment increased primarily capital expenditure new production facilities roche pharmaceuticals genentech goodwill intangible assets increased billion swiss francs mainly bioveris tanox acquisitions groups various inlicensing transactions current assets within current assets inventories accounts receivable slightly higher local currencies largely offset decrease cash marketable securities described surety bond totalling billion swiss francs posted genentech connection city hope litigation nowclassified shortterm debt reduction debt billion swiss francs following redemption million us dollar european medium term notes conversion remaining lyons v notes debt repayments partly offset billion swiss francs additional debt genentech commercial paper program noncurrent current liabilities decrease billion swiss francs due reduction income tax liabilities billion swiss francs reduction billion swiss francs legal provisions following settlements made provision billion swiss francs recorded genentech connection city hope litigation classified shortterm total net assetsequity significant movements equity net income billion swiss francs dividend payments billion swiss francs genentech chugai share repurchases reduced equity billion swiss francs however offset increases equity billion swiss francs sale roches equity together billion swiss francs equity compensation plans currency translation losses billion swiss francs mainly driven fall us dollar compared groups reporting currency swiss franc strong financial condition group remains solidly financed equity including minority interests representing total assets total assets financed longterm pensions postemployment benefits postemployment benefit plans classified defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions expenses groups defined contribution plans million swissfrancs million swiss francs plans classified defined benefit plans even groups potential obligation relatively minor relatively remote possibility arising funding asset management groups various defined benefit plans overseen corporate level plans usually established trusts independent group funded payments group employees cases plan unfunded group pays pensions retired employees directly financial resources funding status defined benefit pension postemployment benefit plans mchf mchf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation finance report roche group financial review funding status overall groups defined benefit plans continue adequately funded funding status increasing main movements came reduction defined benefit obligations following increase discount rates valuations expenses recorded income statement pension expenses relating groups defined benefit plans million swiss francs compared million swiss francs increase mainly due changes discount rates adopted end increased life expectancy assumptions based revised actuarial assumptions end pension expenses expected broadly inline full details groups pensions postemployment benefits given note consolidated financial statements roche securities price development roche securities performed broadly line msci european pharmaceutical index lower compared usbased counterparts benefited higher performance versus arelatively low baseline share price market capitalisation december change share price chf nonvoting equity security genussscheinprice chf market capitalisation billions chf roche ranked number among peer group healthcare companies listed terms total shareholder return tsr ie share price growth plus dividends measured swiss francs actualexchange rates yearend return roche share roche nonvoting equity security combined performance share nonvoting equity security compared weighted average return roche peer group actual exchange rates total shareholder return development price tsr roche share roche gs peer group actual exchange rates dec march june sept dec roche share roche gs peer group peer group abbott laboratories amgen astellas astrazeneca bayer becton dickinson biogen idec bristolmyers squibb eli lilly gilead glaxosmithkline johnson johnson merck co novartis pfizer roche sanofiaventis schering plough takeda wyeth finance report roche group financial review dividend board directors proposing increase dividend swiss francs per shareand nonvoting equity security swiss francs approval annual general meeting stconsecutive increase dividend dividend proposal approved shareholders dividend payments shares nonvoting equity securities issue amount billion swiss francs billion swiss francs resulting payout ratio based prices yearend thedividend yield roche share yield nonvoting equity security information roche securities given pages finance report information per share nonvoting equity security chf chf change basic eps diluted eps core eps equity attributable roche shareholders per share dividend per share details please refer notes consolidated financial statements finance report financial risks group manages financial assets liabilities conservative way treasury management supports pharmaceuticals diagnostics businesses activities materially affect groups risk profile asset allocation liquid funds primarily held liquidity reserve funds invested well diversified portfolio highquality fixed income securities prudent asset management approach also evidenced low share equities within portfolio marketable securities group owns additional equity securities kept part groups strategic alliance efforts classified financial longterm assets see note consolidated financial statements cash marketable securities mchf total mchf total cash cash equivalents money market instruments bonds debentures investments shares total cash marketable securities market risks market risk arises changing market prices groups financial assets financial liabilities exposures predominantly related changes foreign exchange rates interest rates equity prices group uses valueatrisk var assess impact market risk financial instruments var data indicates value range within given financial instrument fluctuate preset probability result movements market prices var data table indicate loss level overaperiod one month probability exceeded finance report roche group financial review valueatrisk financial instruments december december mchf mchf var foreign exchange component var interest rate component var price component diversification var total end total var financial assets liabilities million swiss francs million swiss francs foreign exchange var increased mainly due higher hedging levels non us dollar cash flows future royalty income next five years genentech lower contribution interest rate component caused ageing fixedterm liabilities price risk arises mainlyfrom movements prices equity securities group held equity securities market value billion swiss francs billion swiss francs number includes holdings biotechnology companies acquired context licensing transactions scientific collaborations lower holdings equity securities resulted lower var price risk information financial risk management financial risks var methodology included note consolidated financial statements international financial reporting standards roche group using international financial reporting standards ifrs report consolidated results since international accounting standards board iasb published number new revised standards interpretations group implemented january changes relate mainly disclosure items annual financial statements addition group made changes presentation operating results income statement group made presentational changes accurately reflect underlying business improve comparability results healthcare companies allow readers make accurate assessment sustainable earnings capacity group total operating profit unchanged presentational changes effect nonoperating results net income earnings per share full details changes given note consolidated financial statements supplementary presentation materials investor update held november available investor relations section groups website wwwrochecom finance report roche group consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration operating profit associated companies financial income financing costs profit taxes income taxes net income attributable roche shareholders minority interests earnings per share nonvoting equity security group basic chf diluted chf finance report roche group roche group consolidated financial statements roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration operating profit associated companies financial income financing costs profit taxes income taxes profit continuing businesses profit discontinued businesses net income attributable roche shareholders minority interests continuing earnings per share nonvoting equity security businesses group basic chf diluted chf disclosed note operating results income statement restated following presentational changes adopted reconciliation previously published income statement provided note total operating profit unchanged presentational changes effect nonoperating results net income earnings per share finance report roche group roche group consolidated financial statements roche group consolidated balance sheet millions chf december december noncurrent assets property plant equipment goodwill intangible assets associated companies financial longterm assets longterm assets deferred income tax assets postemployment benefit assets total noncurrent assets current assets inventories accounts receivable current income tax assets current assets marketable securities cash cash equivalents total current assets total assets noncurrent liabilities longterm debt deferred income tax liabilities postemployment benefit liabilities provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable accrued current liabilities total current liabilities total liabilities total net assets equity capital reserves attributable roche shareholders equity attributable minority interests total equity disclosed note split noncurrent assets balance sheet restated following presentational changes adopted reconciliation previously published balance sheet provided note total noncurrent assets unchanged finance report roche group roche group consolidated financial statements roche group consolidated cash flow statement millions chf year ended december cash flows operating activities cash generated operations increase decrease working capital payments made defined benefit postemployment plans utilisation legal environmental provisions utilisation restructuring provisions operating cash flows cash flows operating activities income taxes paid income taxes paid total cash flows operating activities cash flows investing activities purchase property plant equipment purchase intangible assets disposal property plant equipment disposal intangible assets disposal products business combinations divestments discontinued businesses divestments subsidiaries interest dividends received sales marketable securities purchases marketable securities investing cash flows total cash flows investing activities cash flows financing activities proceeds issue longterm debt instruments repayment redemption longterm debt instruments increase decrease longterm debt transactions equity instruments increase decrease shortterm borrowings interest dividends paid exercises equitysettled equity compensation plans genentech chugai share repurchases financing cash flows total cash flows financing activities net effect currency translation cash cash equivalents increase decrease cash cash equivalents cash cash equivalents january cash cash equivalents december finance report roche group roche group consolidated financial statements roche group consolidated statement recognised income expense millions chf year ended december availableforsale investments valuation gains losses taken equity transferred income statement sale impairment cash flow hedges gains losses taken equity transferred income statement transferred initial balance sheet carrying value hedged items exchange differences translation foreign operations defined benefit postemployment plans actuarial gains losses limit asset recognition income taxes items taken directly transferred equity net income recognised directly equity net income recognised income statement total recognised income expense attributable roche shareholders minority interests total effect changes accounting policy attributable roche shareholders minority interests total finance report roche group roche group consolidated financial statements roche group consolidated statement changes equity millions chf roche minority shareholders interests total year ended december january net income recognised directly equity net income recognised income statement total recognised income expense dividends paid transactions equity instruments equity compensation plans genentech chugai share repurchases convertible debt instruments changes minority interests december year ended december january net income recognised directly equity net income recognised income statement total recognised income expense dividends paid transactions equity instruments equity compensation plans genentech chugai share repurchases convertible debt instruments changes minority interests december finance report notes roche group consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements summary significant accounting policies basis preparation consolidated financial statements consolidated financial statements roche group prepared accordance international financial reporting standards ifrs comply swiss law prepared using historical cost convention except disclosed accounting policies certain items including derivatives availableforsale investments shown fair value approved issue board directors january subject approval annual general meeting shareholders march preparation consolidated financial statements requires management make estimates assumptions affect reported amounts revenues expenses assets liabilities disclosure contingent liabilities date financial statements future estimates assumptions based managements best judgement date financial statements deviate actual circumstances original estimates assumptions modified appropriate year circumstances change changes accounting policies arise application new revised standards interpretations applied retrospectively unless otherwise specified transitional requirements particular standard interpretation retrospective application requires results comparative period opening balances period restated new accounting policy always applied cases transitional requirements particular standard interpretation specify changes applied prospectively prospective application requires new accounting policy applied results current period comparative period restated addition comparatives reclassified orextended previously reported results take account presentational changes consolidation policy financial statements consolidated financial statements roche holding ltd company registered switzerland subsidiaries group subsidiaries companies controlled directly indirectly roche holding ltd control defined power govern financial operating policies enterprise obtain benefits activities control normally evidenced roche holding ltd owns either directly indirectly voting rights currently exercisable potential voting rights companys share capital special purpose entities consolidated substance relationship special purpose entity controlled group companies acquired year consolidated date control istransferred group subsidiaries divested included date control passes group intercompany balances transactions resulting unrealised income eliminated full investments associated companies accounted equity method companies group exercises power exercise significant influence control normally evidenced group owns voting rights currently exercisable potential voting rights company balances transactions associated companies result unrealised income eliminated extent groups interest associated company interests joint ventures reported using linebyline proportionate consolidation method finance report roche group notes roche group consolidated financial statements segment reporting determination groups operating segments based organisation units information reported groups management group two divisions pharmaceuticals diagnostics revenues primarily generated sale prescription pharmaceutical products diagnostic instruments reagents consumables respectively divisions also derive revenue sale licensing products technology third parties within pharmaceuticals division three subdivisions roche pharmaceuticals genentech chugai three subdivisions separate management reporting structures within pharmaceuticals division considered separately reportable operating segments certain headquarter activities reported corporate consist corporate headquarters including corporate executive committee corporate communications corporate human resources corporate finance including treasury taxes pension fund management corporate legal corporate safety environmental services effective january groups management concluded remaining residual balances divested vitamins fine chemicals business consumer health otc business considered part groups continuing businesses reported corporate segment prior presented discontinued businesses see note transfer prices operating segments set arms length basis operating assets liabilities consist property plant equipment goodwill intangible assets trade receivablespayables inventories assets liabilities provisions reasonably attributed reported operating segments nonoperating assets liabilities mainly include current deferred income tax balances postemployment benefit assetsliabilities financial assetsliabilities cash marketable securities investments debt foreign currency translation group companies use local currency functional currency certain group companies use othercurrencies namely us dollars swiss francs euros functional currency currency primary economic environment entity operates local transactions currencies initially reported using exchange rate date transaction gains losses settlement transactions gains losses translation monetary assets liabilities denominated currencies included income except qualifying cash flow hedges arise monetary items substance form part groups net investment foreign entity cases gains losses deferred equity upon consolidation assets liabilities group companies using functional currencies swiss francs foreign entities translated swiss francs using yearend rates exchange sales costs expenses net income cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly equity disposal foreign entity identified cumulative currency translation differences within equity relating foreign entity recognised income part gain loss divestment revenues sales represent amounts received receivable goods supplied customers deducting trade discounts cash discounts volume rebates exclude value added taxes taxes directly linked sales revenues sale products recognised upon transfer customer significant risks rewards trade discounts cash discounts volume rebates recorded accrual basis consistent recognition related sales estimates expected sales returns chargebacks rebates including medicaid united states similar rebates countries also deducted sales recorded accrued liabilities provisions deduction accounts receivable estimates based analyses existing contractual legislatively mandated obligations historical trends groups experience revenues recorded earned services performed necessary single transactions split separately identifiable components reflect substance transaction conversely two transactions may considered together revenue recognition purposes commercial effect understood without reference series transactions whole finance report roche group notes roche group consolidated financial statements cost sales cost sales includes corresponding direct production costs related production overheads goods sold services rendered royalties alliance collaboration expenses including collaboration profitsharing arrangements also reported part cost sales startup costs validation achievement normal production capacity expensed incurred research development addition internal research development activities group also party inlicensing similar arrangements alliance partners group may also acquire inprocess research development assets either business combinations purchases specific assets internal research costs charged income incurred internal development costs capitalised intangible assets identifiable asset completed generate probable future economic benefits cost asset measured reliably group currently internal development costs qualify capitalisation intangible assets internal development costs therefore charged income incurred since criteria recognition anasset met inprocess research development assets acquired either inlicensing arrangements business combinations separate purchases capitalised intangible assets described available use intangible assets amortised straightline basis period expected benefit andare reviewed impairment reporting date licensing milestone upfront receipts payments royalty income recognised accruals basis accordance substance respective licensing agreements certain group companies receive third parties upfront milestone similar payments relating sale licensing products technology revenue associated performance milestones recognised based achievement deliverables defined respective agreements upfront payments licence fees subsequent deliverables initially reported deferred income recognised income earned period development collaboration manufacturing obligation payments made group companies third parties associated companies items capitalised asintangible assets accounting reporting transactions roche genentech chugai within groups consolidated financial statements transactions balances consolidated subsidiaries genentech chugai roche group subsidiaries eliminated consolidation genentech chugai considered separately reportable operating segments purposes groups operating segment disclosures note additional information relating genentech chugai results given notes respectively profits product sales roche pharmaceuticals genentech chugai operating segments recorded part segment results operating segment making sale unrealised internal profits inventories sold one operating segment another yet sold toexternal customers balance sheet date eliminated consolidation entry pharmaceuticals division level additionally results operating segment may include income received another operating segment respect royalties licensing milestone upfront payments transfers respect research collaborations finance report roche group notes roche group consolidated financial statements recognised income segment results operating segment receiving income consistently accounting policies applied thirdparty transactions set financial statements corresponding expenses recorded operating segment eliminate apharmaceuticals division level employee benefits wages salaries social security contributions paid annual leave sick leave bonuses nonmonetary benefits accrued year associated services rendered employees group group provides longterm employee benefits cost accrued match rendering services employees concerned liabilities longterm employee benefits discounted take account thetime value money material pensions postemployment benefits employees covered defined benefit defined contribution postemployment plans sponsored group companies groups contributions defined contribution plans charged appropriate income statement heading within operating results year relate accounting reporting defined benefit plans based recent actuarial valuations defined benefit obligations service costs calculated using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth longterm expected rates return plan assets discount rates based market yields highquality corporate bonds country concerned past service costs allocated average period benefits become vested current past service costs charged appropriate income statement heading within operating results pension plan administration funding overseen corporate level settlement gains losses resulting changes funding arrangements reported general administration expenses within corporate segment expected returns plan assets interest costs charged financial income financing costs respectively actuarial gains losses consist differences assumptions actual experiences effects changes actuarial assumptions recorded directly equity pension assets liabilities different defined benefit plans offset unless group legally enforceable right touse surplus one plan settle obligations plan recognition pension assets limited total present value future refunds plans reductions future contributions plans cumulative unrecognised past service costs adjustments arising limit recognition assets defined benefit plans recorded directly equity equity compensation plans certain employees group participate equity compensation plans including separate plans genentech chugai fair value equity compensation awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading within operating results equitysettled plans increase equity recorded subsequent cash flows exercises vested awards recorded increase equity cash settled plans liability recorded measured fair value balance sheet date movements fair value recorded appropriate income statement heading within operating results subsequent cash flows exercise vested awards recorded reduction liability property plant equipment property plant equipment initially recorded cost purchase construction include costs directly attributable bringing asset location condition necessary capable operating manner intended management include items costs site preparation installation assembly costs professional fees net costs testing whether asset functioning properly including validation costs also included initially recorded cost construction interest borrowing costs incurred respect qualifying assets capitalised included carrying value assets finance report roche group notes roche group consolidated financial statements property plant equipment depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows land improvements years buildings years machinery equipment years diagnostic instruments years office equipment years motor vehicles years parts item property plant equipment different useful lives accounted separate components estimated useful life assets regularly reviewed necessary future depreciation charge accelerated repairs maintenance costs expensed incurred leases group lessee leases property plant equipment group substantially ofthe risks rewards ownership classified finance leases finance leases capitalised start lease fair value present value minimum lease payments lower rental obligation net finance charges reported within debt assets acquired finance leases depreciated accordance groups policy property plant equipment reasonable certainty group obtain ownership end lease term asset depreciated shorter lease term itsuseful life interest element lease payment charged income lease term based effective interest rate method leases substantially risks rewards ownership transferred group classified operating leases payments made operating leases charged income straightline basis period lease group lessor primarily occurs diagnostics division assets subject finance leases initially reported receivables amount equal net investment lease assets subject operating leases reported within property plant equipment lease income finance leases subsequently recognised earned income term lease based effective interest rate method lease income operating leases recognised lease term straightline basis business combinations goodwill business combinations accounted using purchase method accounting cost acquisition consideration given exchange control identifiable assets liabilities contingent liabilities acquired company consideration includes cash paid plus fair value date exchange assets given liabilities incurred assumed equity instruments issued group cost acquisition also includes directly attributable costs acquired net assets identifiable assets liabilities contingent liabilities initially recognised fair value group acquire ownership acquired company minority interest recorded minoritys proportion fair value acquired net assets goodwill recorded surplus cost acquisition groups interest fair value acquired net assets goodwill fair value adjustments recorded assets liabilities acquired company functional currency company goodwill amortised assessed possible impairment balance sheet date additionally tested annually impairment goodwill may also arise upon investments associated companies surplus cost investment groups share fair value net identifiable assets goodwill recorded within investments associated companies intangible assets purchased patents licences trademarks intangible assets initially recorded cost assets acquired business combination fair value allocated acquisition accounting intangible assets amortised useful lives straightline basis beginning point available use estimated useful life lower legal duration economic useful life estimated useful life intangible assets regularly reviewed finance report roche group notes roche group consolidated financial statements impairment property plant equipment intangible assets impairment assessment carried evidence asset may impaired addition intangible assets yet available use tested impairment annually recoverable amount asset higher fair value less costs sell value use less carrying amount carrying amount reduced recoverable amount reduction reported income statement impairment loss value use calculated using estimated cash flows generally fiveyear period extrapolating projections subsequent years discounted using appropriate longterm pretax interest rate impairment loss arises useful life asset question reviewed necessary future depreciationamortisation charge accelerated impairment financial assets discussed financial assets policy impairment goodwill goodwill assessed possible impairment balance sheet date additionally tested annually impairment goodwill allocated cashgenerating units described note recoverable amount cashgenerating unit higher fair value less costs sell value use less carrying amount impairment carrying amount recorded methodology used impairment testing described note inventories inventories stated lower cost net realisable value cost finished goods work process includes raw materials direct labour directly attributable costs overheads based upon normal capacity production facilities cost determined using weighted average method net realisable value isthe estimated selling price less cost completion selling expenses accounts receivable accounts receivable carried original invoice amount less allowances made doubtful accounts trade discounts cash discounts volume rebates similar allowances allowance doubtful accounts recorded difference carrying amount recoverable amount objective evidence group able collect amounts due trade discounts cash discounts volume rebates similar allowances recorded accrual basis consistent recognition related sales using estimates based existing contractual obligations historical trends groups experience longterm accounts receivable discounted take account time value money material cash cash equivalents cash cash equivalents include cash hand time call current balances banks similar institutions balances reported cash readily convertible known amounts cash subject insignificant risk changes value maturity three months less date ofacquisition definition also used cash flow statement provisions provisions recognised legal constructive obligation incurred probably lead outflow resources reasonably estimated particular restructuring provisions recognised group detailed formal plan either commenced implementation announced provisions recorded estimated ultimate liability expected arise taking account foreign currency effects arising translation functional currency swiss francs time value money material contingent liability disclosed existence obligation confirmed future events amount obligation measured reasonable reliability contingent assets recognised disclosed inflow economic benefits probable fair values fair value amount financial asset liability instrument could exchanged knowledgeable willing parties arms length transaction determined reference quoted market prices use established estimation techniques option pricing models estimated discounted values cash flows fair values financial assets liabilities balance sheet date materially different reported carrying values unless specifically mentioned notes consolidated financial statements finance report roche group notes roche group consolidated financial statements financial assets financial assets principally investments including marketable securities classified either fairvalue throughprofitorloss availableforsale heldtomaturity loans receivables fairvaluethrough profitorloss financial assets either classified heldfortrading designated upon initial recognition heldfortrading financial assets acquired principally generate profit shortterm fluctuations price financial assets designated fairvaluethroughprofitorloss results relevant information eliminating measurement recognition inconsistency heldtomaturity financial assets securities fixed maturity group intent ability hold maturity loans receivables loans longterm financial assets created group acquired issuer primary market nonderivative financial assets fixed determinable payments quoted active market financial assets considered availableforsale financial assets initially recorded fair value including transaction costs except assets designated fairvaluethroughprofitorloss exclude transaction costs purchases sales recognised settlement date fairvaluethroughprofitorloss financial assets subsequently carried fair value changes fair value recorded financial income period arise heldtomaturity financial assets subsequently carried amortised cost using effective interest rate method availableforsale financial assets subsequently carried fair value unrealised changes fair value recorded equity except interest calculated using effective interest rate method foreign exchange components availableforsale financial assets sold impaired otherwise disposed cumulative gains losses previously recognised equity included financial income current period loans receivables subsequently carried amortised cost financial assets assessed possible impairment balance sheet date impairment charge recorded objective evidence impairment issuer bankruptcy default significant financial difficulty addition availableforsale equity securities market value original cost net previous impairment considered impaired availableforsale equity securities market value original cost net previous impairment sustained sixmonth period also considered impaired decreases market price less original cost net previous impairment also less sustained sixmonth period considered objective evidence impairment movements fair value recorded equity objective evidence impairment asset sold otherwise disposed financial assets carried amortised cost impairment charge difference carrying value recoverable amount calculated using estimated future cash flows discounted using original effective interest rate availableforsale financial assets impairment charge amount currently carried equity difference original cost net previous impairment fairvalue financial assets derecognised contractual rights cash flows assets expire group sells otherwise disposes contractual rights cash flows including situations group retains contractual rights assumes contractual obligation pay cash flows third party derivatives derivative financial instruments initially recorded subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments discussed hedging policy changes fair value recorded financial income period arise embedded derivatives recognised separately closely related host contract host contract carried atamortised cost hedging purposes hedge accounting hedging relationships may three types fair value hedges hedges particular risks may change fair value recognised asset liability cash flow hedges hedges particular risks may change amount timing future cash flows hedges net investment foreign entity hedges particular risks may change carrying value net assets foreign entity finance report roche group notes roche group consolidated financial statements qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship particular derivatives reported fair value changes fair value included financial income qualifying fair value hedges hedging instrument recorded fair value hedged item recorded previous carrying value adjusted changes fair value attributable hedged risk anychanges fair values reported financial income qualifying cash flow hedges hedging instrument recorded fair value portion change fair value effective hedge included equity remaining ineffective portion reported financial income hedging relationship hedge foreign currency risk firm commitment highly probable forecasted transaction results recognition nonfinancial asset liability cumulative changes fair value hedging instrument recorded equity included initial carrying value asset liability date recognition qualifying cash flow hedges cumulative changes fair value hedging instrument recorded equity included financial income forecasted transaction affects net income qualifying hedges net investment foreign entity hedging instrument recorded fair value portion change fair value effective hedge included equity remaining ineffective portion recorded financial income hedging instrument derivative equity cases entity disposed cumulative changes fair value hedging instrument recorded equity reclassified income debt instruments debt instruments initially recorded cost proceeds received net transaction costs subsequently reported amortised cost using effective interest method discount net proceeds received principal value due redemption amortised duration debt instrument recognised part financing costs using effective interest rate method certain debt instruments may designated fairvaluethroughprofitorloss results relevant information eliminates significantly reduces measurement recognition inconsistencies debt instruments reported fair value based quoted prices active market movements fair value reported within financial income debt instruments designated fairvaluethroughprofitorloss disclosed note bifurcation carried upon issue convertible debt instruments initial carrying value liability element calculated using market interest rate equivalent nonconvertible instrument remainder net proceeds allocated equity conversion option reported equity deferred income tax liabilities liability element subsequently reported amortised cost fairvaluethroughprofit orloss designated taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based income property capital taxes included within general administration expenses liabilities income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries recognised probable earnings remitted inthe foreseeable future deferred income tax assets liabilities recognised temporary differences tax bases assets liabilities carrying amounts financial statements deferred income tax assets relating carryforward unused tax losses recognised extent probable future taxable profit available unused tax losses utilised finance report roche group notes roche group consolidated financial statements current deferred income tax assets liabilities offset income taxes levied taxation authority legally enforceable right offset deferred income taxes determined based currently enacted tax rates applicable tax jurisdiction group operates discontinued businesses noncurrent assets held sale discontinued business component groups business represents separate major line business geographical area operations subsidiary acquired exclusively view resale reclassification discontinued business occurs upon disposal operation meets criteria classified held sale earlier disposal group group assets disposed group single transaction together liabilities directly associated assets transferred transaction assets liabilities disposal group reclassified held sale value recovered principally asale rather continuing use disposal group must available sale current condition sale must highly probable immediately classification held sale measurement assets liabilities disposal group updated accordance applicable accounting policies initial classification held sale disposal groups recognised lower carrying amount fair value less costs sell impairment losseson initial classification held sale included income statement equity instruments groups holdings equity instruments recorded deduction equity original purchase cost consideration received subsequent resale equity instruments movements reported changes equity instruments acquired primarily meet potential obligations employees may arise respect certain groups equity compensation plans management judgements made applying accounting policies application groups accounting policies may require management make judgements apart involving estimates significant effect amounts recognised consolidated financial statements management judgement particularly required assessing substance transactions complicated structure legal form include limited following areas revenue recognition nature groups business many sales transactions asimple structure sales agreements may consist multiple components occurring different times group also party various outlicensing agreements involve upfront milestone payments may occur several years agreements may also involve certain future obligations revenue recognised managements judgement significant risks rewards ownership transferred group retain continuing managerial involvement effective control goods sold obligation fulfilled transactions result cash receipts initially recognised deferred income released income subsequent periods basis theperformance conditions specified agreement consolidation subsidiaries associated companies group periodically undertakes transactions may involve obtaining right control significantly influence operations companies transactions include acquisition part equity companies purchase certain assets assumption certain liabilities contingent liabilities companies entering alliance agreements companies also included transactions involving special purpose entities similar vehicles cases management makes assessment whether group right control significantly influence companys operations based assessment company consolidated subsidiary associated company making assessment management considers underlying economic substance transaction contractual terms finance report roche group notes roche group consolidated financial statements business combinations group acquires control another business cost acquisition hasto allocated assets liabilities contingent liabilities acquired business residual recorded goodwill process involves management making assessment fair value items management judgement particularly involved recognition measurement following areas intellectual property may include patents licences trademarks similar rights currently marketed products also rights scientific knowledge associated projects currently research development phases contingencies legal environmental matters recoverability accumulated tax losses acquired company cases management makes assessment based underlying economic substance items concerned contractual terms order fairly present items amount could exchanged settled knowledgeable willing parties arms length transaction leasesthe group party leasing arrangements lessee lessor treatment leasing transactions financial statements mainly determined whether lease considered operating lease finance lease making assessment management looks substance lease well legal form makes judgement whether substantially risks rewards ownership transferred arrangements take legal form lease nevertheless convey right use asset also covered assessments key assumptions sources estimation uncertainty preparation consolidated financial statements conformity ifrs requires management make estimates assumptions affect application policies reported amounts assets liabilities income expenses related disclosures estimates underlying assumptions based historical experience various factors believed reasonable circumstances results form basis making judgements carrying values assets liabilities readily apparent sources actual results may differ estimates estimates underlying assumptions reviewed ongoing basis changes accounting estimates may necessary changes circumstances estimate based result new information experience changes recognised period estimate revised key assumptions future key sources estimation uncertainty significant risk causing material adjustment carrying value assets liabilities within next twelve months aredescribed sales allowances group provisions accruals expected sales returns chargebacks rebates including medicaid united states similar rebates countries december total million swiss francs estimates based analyses existing contractual legislatively mandated obligations historical trends groups experience management believes total provisions accruals items adequate based upon currently available information deductions based management estimates may subject change better information becomes available changes arise could impact provisions accruals recognised balance sheet infuture periods consequently level sales recognised income statement future periods property plant equipment intangible assets including goodwillthe group property plant equipment carrying value million swiss francs disclosed note goodwill carrying value million swiss francs see note intangible assets carrying value million swiss francs see note assets reviewed annually impairment described assess whether impairment exists estimates made future cash flows expected result use asset eventual disposal actual outcomes could vary significantly estimates discounted future cash flows factors changes planned use buildings machinery equipment closure facilities presence absence competition technical obsolescence lower anticipated sales products capitalised rights could result shortened useful lives impairment finance report roche group notes roche group consolidated financial statements pensions postemployment benefitsmany groups employees participate postemployment defined benefit plans calculations recognised assets liabilities plans based upon statistical actuarial calculations particular present value defined benefit obligation impacted assumptions discount rates used arrive present value future pension liabilities assumptions future increases salaries benefits furthermore groups independent actuaries use statistically based assumptions covering areas future withdrawals participants plan estimates life expectancy december present value groups defined benefit obligation million swiss francs funded plans million swiss francs unfunded plans see note actuarial assumptions used may differ materially actual results due changes market economic conditions higher lower withdrawal rates longer shorter life spans participants changes factors assessed differences could impact assets liabilities recognised balance sheet future periods legal provisionsgroup companies party various legal proceedings significant matters described note legal provisions december total million swiss francs additional claims could made might covered existing provisions insurance assurance increase scope matters future lawsuits claims proceedings investigations material changes arise could impact provisions recognised balance sheet future periods environmental provisions group provisions environmental remediation costs december total million swiss francs disclosed note material components environmental provisions consist costs fully clean refurbish contaminated sites treat contain contamination certain sites future remediation expenses affected number uncertainties include limited detection previously unknown contaminated sites method extent remediation percentage waste material attributable group remediation sites relative attributable parties financial capabilities potentially responsible parties management believes total provisions environmental matters adequate based upon currently available information however given inherent difficulties estimating liabilities area guaranteed additional costs incurred beyond amounts accrued effect resolution environmental matters results operations predicted due uncertainty concerning amount timing future expenditures changes arise could impact provisions recognised balance sheet future periods income taxesat december net liability current income taxes million swiss francs netliability deferred income taxes million swiss francs disclosed note significant estimates required determine current deferred assets liabilities income taxes estimates based interpretations existing tax laws regulations management believes estimates reasonable recognised liabilities income taxrelated uncertainties adequate various internal external factors may favourable unfavourable effects income tax assets liabilities factors include limited changes tax laws regulations andor rates changing interpretations existing tax laws regulations future levels research development spending changes overall levels pretax earnings changes arise could impact assets liabilities recognised balance sheet future periods changes accounting policies group adopted certain new revised international financial reporting standards interpretations effective january description changes material group effect consolidated financial statements given ifrs financial instruments disclosures new standard replaces disclosure requirements previously contained ias financial instruments presentation requires additional disclosure concerning significance groups financial instruments nature extent risks arising instruments manner risks managed presentation requirements required ias remain unchanged disclosure requirements ifrs include qualitative quantitative information risk exposure arising financial instruments particular credit risk liquidity risk market risk standard also requires qualitative disclosure managements objectives policies processes managing risks hence providing overview groups use exposure financial instruments given note finance report roche group notes roche group consolidated financial statements result implementation ifrs classification two noncurrent asset balances changed balance sheet december restated total noncurrent assets unchanged pension reimbursement rights classified postemployment benefit assets finance lease receivables classified financial longterm assets restated noncurrent assets balance sheet december millions chf pension finance originally reimburse lease group published ment rights receivables restated financial longterm assets longterm assets postemployment benefit assets ifrs operating segments new standard replaces ias segment reporting requires changes methodology format segment reporting group determined reportable operating segments new standard primary business segments old standard new standard requires additional disclosure operating segments given note unrealised internal profits inventories sold one operating segment another yet sold external customers balance sheet date eliminated consolidation entry previously elimination allocated originating operating segment segment results restated following presentational change restated pharmaceuticals divisional information year ended december millions chf roche pharma pharma genentech chugai division originally published operating profit including unrealised profits inventories restated operating profit elimination profit within division total ias revised presentation financial statements capital disclosuresthe revisions ias require additional disclosure concerning groups objectives policies processes managing capital given note ias revised borrowing costs revised standard requires interest borrowing costs incurred respect qualifying assets capitalised included carrying value assets groups previous accounting policy costs expensed interest costs group applied new standard prospectively january borrowing costs totalling million swiss francs using rate capitalised property plant equipment would expensed previous accounting policy comparative results restated new accounting policy applied group would capitalised additional million swiss francs property plant equipment financing costs would lower amount positive impact chf earnings per share nonvoting equity security basic diluted would similar positive impact revised standard applied retrospectively presentation operating results income statement income statement year ended december restated following presentational changes adopted group made presentational changes accurately reflect underlying business improve comparability results healthcare companies allow readers make accurate assessment sustainable earnings capacity group total operating profit unchanged presentational changes effect nonoperating results net income earnings per share changes applied retrospectively listed finance report roche group notes roche group consolidated financial statements intangible assets amortisation impairment intangible assets longer reported separate line reported part cost sales intangibles relating marketed products part research development intangibles relating technology development including impairment intangibles yet available use alliance royalty expenses royalties alliance collaboration expenses including collaboration profitsharing arrangements reported part cost sales previously included marketing distribution general administration depending upon terms particular agreement additionally royalty expenses payable royalty income reported part royalties operating income accurately reflect substance underlying transactions previously expenses included general administration phase iv similar costs costs arise pharmaceuticals division reported part research development previously costs included marketing distribution general administration depending nature restated income statement year ended december millions chf originally intangible alliances published assets royalties phase iv restated group sales royalties operating income cost sales marketing distribution research development general administration amortisation impairment intangible assets operating profit pharmaceuticals division sales royalties operating income cost sales marketing distribution research development general administration amortisation impairment intangible assets operating profit diagnostics division sales royalties operating income cost sales marketing distribution research development general administration amortisation impairment intangible assets operating profit future changes ifrs group early adopted ifrs operating segments ias revised borrowing costs required implemented january latest group expect new interpretations effective january significant effect groups results financial position group currently assessing potential impacts new revised standards effective january beyond include revisions ias presentation financial statements revisions ifrs business combinations ias consolidated separate financial statements ifrs share based payment finance report roche group notes roche group consolidated financial statements operating segment information divisional information millions chf pharmaceuticals division diagnostics division corporate group revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination interdivisional revenue total segment results operating profit elimination interdivisional profit total capital expenditure business combinations additions property plant equipment additions intangible assets total capital expenditure segment information depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets equity compensation plan expenses finance report roche group notes roche group consolidated financial statements pharmaceuticals subdivisional information millions chf roche pharmaceuticals genentech chugai pharmaceuticals division revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination revenue within division total segment results operating profit elimination profit within division total capital expenditure business combinations additions property plant equipment additions intangible assets total capital expenditure segment information depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets equity compensation plan expenses finance report roche group notes roche group consolidated financial statements net operating assets millions chf assets liabilities net assets roche pharmaceuticals genentech chugai elimination within division pharmaceuticals division diagnostics division corporate total operating nonoperating group information geographical area millions chf revenues external customers noncurrent assets royalties operating property plant goodwill sales income equipment intangible assets switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total finance report roche group notes roche group consolidated financial statements revenues external customers noncurrent assets royalties operating property plant goodwill sales income equipment intangible assets switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total sales allocated geographical areas destination according location customer royalties operating income allocated according location group company receives revenue european union information based members eu december comparative information restated include bulgaria romania within european union segment major customers us national wholesale distributor amerisourcebergen corp represented approximately billion swiss francs billion swiss francs groups revenues revenues genentech operating segment residual roche pharmaceuticals diagnostics segments group also reported substantial revenues us national wholesale distributors cardinal health inc mckesson corp total three customers represented approximately quarter groups revenues majority genentech genentech effective september roche group acquired majority interest approximately genentech inc biotechnology company united states june group exercised option acquire remaining shares genentech june point genentech became owned subsidiary group july october march group completed public offerings genentechs common stock reduced groups majority interest groups ownership genentech decreased due conversion redemption lyons iv us dollar exchangeable notes december groups interest genentech common stock genentech publicly traded listed new york stock exchange symbol dna genentech prepares financial statements conformity accounting principles generally accepted united states us gaap filed quarterly basis us securities exchange commission sec roches relationship genentech genentech entered certain agreements roche discussed affiliation arrangementsas result june redemption genentechs special common stock subsequent public offerings genentech amended certificate incorporation bylaws entered oramended certain affiliation arrangements roche amongst matters cover following areas finance report roche group notes roche group consolidated financial statements roches rights shareholder roches rights nominate members genentechs board directors certain limitations roches ability buy sell genentechs common stock process roche may effect merger genentech roche approval directors designated roche genentech seek make significant business acquisitions divestments approval directors designated roche genentech seek issue repurchase redeem capital stock genentech issues additional shares common stock connection equity compensation plans may issue additional shares purposes affects roches percentage ownership interest affiliation agreement roche genentech provides amongst matters genentech establish stock repurchase programme maintain roches percentage ownership interest genentech licensing agreements july roche genentech agreed amended restated licensing marketing agreement granting roche option license use sell genentechs products nonus markets licensing marketing agreement subsequently amended delete add certain genentech products roches commercialisation marketing rights canada addition roche genentech july licensing marketing agreement relating antiher antibodies herceptin pertuzumab providing roche exclusive marketing rights outside us depending specific circumstances terms agreement may result payments armslength basis roche genentech following matters fees extend roches option license product partial reimbursement genentechs previously incurred development costs roche exercises option license product milestones similar payments dependent upon achievement agreed objectives performance targets royalties roches aggregate sales product manufacturing agreements genentech agreed general manufacture supply roche clinical requirements cost commercial requirements cost plus basis roche right manufacture genentechs products certain circumstances july roche genentech signed two new product supply agreements umbrella manufacturing supply agreement umbrella agreement supersedes existing product supply agreements agreement roche agreed purchase specified amounts herceptin avastin perpetual basis either party may order collaboration products including herceptin avastin shortterm supply agreement shortterm agreement supplements terms umbrella agreement agreement roche agreed purchase specified amounts herceptin avastin mabtherarituxan research collaboration agreementin april roche genentech entered research collaboration agreement outlines process parties may agree conduct share costs joint research certain molecules agreement outlines development commercialisation efforts coordinated respect select molecules including financial provisions number different development commercialisation scenarios undertaken either parties tax sharing agreementroche genentech tax sharing agreement relates us state local tax returns consolidated combined genentech calculates tax liability refund group state local jurisdictions genentech standalone entity differences ifrs us gaap due certain consolidation entries differences requirements international financial reporting standards ifrs us gaap differences genentechs standalone financial results us gaap basis financial results genentech consolidated roche group accordance ifrs finance report roche group notes roche group consolidated financial statements reconciliation genentech results usd chf usd chf millions millions millions millions operating income us gaap basis recurring redemption tanox costs equity compensation plan expenses us gaap basis tanox acquisition accounting us gaap basis special litigation items operating income nonus gaap basis add deduct differences consolidation entries add back redemption costs equity compensation plan expenses ifrs basis capitalised inprocess research development differences consolidation entries operating profit ifrs basis add deduct nonoperating items ifrs basis financial income financing costs consolidation entries income taxes net income ifrs basis minority interest percentage average year income applicable minority interest ifrs basis translated usd chf usd chf effective january group implemented ifrs sharebased payment ifrs financial statements amongst matters standard requires fair value equity compensation plans awarded employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading standard also requires retrospective application within certain transitional requirements pretax expense million us dollars million swiss francs relating plans genentech recorded million us dollars million swiss francs effective january genentech implemented us statement financial accounting standards r sharebased payment fas r us gaap financial statements amongst matters requires companies reporting us gaap recognise compensation expenses plans due different dates first application measurement requirements transitional arrangements fas r ifrs theexpenses recorded genentech us gaap financial statements equity compensation plans expenses recorded roche group ifrs financial statements plans group implemented ias revised intangible assets ifrs financial statements amongst matters revised standard typically results intangible assets recognised inlicensing arrangements similar research development alliances genentechs us gaap financial statements expenditure would usually recorded research development expenses differences ifrs us gaap relatively minor impact genentech share repurchases april genentechs board directors approved extension existing stock repurchase programme authorising genentech repurchase million shares genentechs common stock total billion us dollars june since programmes inception genentech repurchased approximately million shares total approximately billion us dollars genentech repurchased common stock worth million us dollars million swiss francs million usdollars million swiss francs finance report roche group notes roche group consolidated financial statements genentech prepaid share repurchase program november genentech entered prepaid share repurchase arrangement financial institution million us dollars genentechs shares purchased open market financial institution january march prepaid amount recorded equity december purposes groups consolidation minority interests calculated assuming equivalent number shares repurchased based amount prepayment genentech share price month end accordingly roche groups ownership december estimated purposes consolidation financial statements manufacturing agreements lonza effective december genentech sold whollyowned subsidiary genentech espaa including manufacturing facility porrio spain lonza group ltd lonza million us dollars millionus dollars received cash remaining balance received lonza series payments following three years part agreement genentech entered shortterm supply contract lonza production avastin using portion production capacity porrio facility loss divestment genentech espaa millions chf consideration cash present value unsecured receivables lonza total consideration net assets disposed property plant equipment net assets loss divestment time genentech entered supply agreement manufacture certain genentech products lonzas facility construction singapore currently expected receive us food drug administration fda licensure genentech committed fund precommissioning production qualification costs facility upon fda licensure genentech committed purchase products successfully manufactured facility period three years commissioning facility estimated total cost pre postcommissioning commitments approximately million us dollars genentech also received exclusive option purchase lonza singapore facility period one year fda licensure purchase price million us dollars regardless whether purchase option exercised genentech obliged make milestone payment million us dollars certain performance milestones met facility constructed accounting purposes due nature supply agreement genentechs involvement construction buildings genentech considered owner assets construction period even though funds toconstruct building shell infrastructure costs paid lonza genentech also entered loan agreement lonza advance million us dollars lonza construction singapore facility majority expected advanced majority funds advanced lonza unless lonzas securitisation obligations mutually agreed upon parties genentech exercises option purchase facility outstanding advances may offset purchase price genentech exercise purchase option advances may offset supply purchases december construction progress totalling million swiss francs million swiss francs capitalised corresponding net financing obligation totalling million swiss francs mil lion swiss francs recorded noncurrent liabilities finance report roche group notes roche group consolidated financial statements leasing arrangements december genentech entered master lease agreement slough ssf llc slough development property adjacent genentechs south san francisco site development includes total eight buildings subject separate agreements contemplated master lease agreement slough developer construct building shell building genentech finish interior building laboratory office space applicable construction first buildings completed point lease term buildings deemed begin construction final buildings expected completed lease term expires twelve years occupation final building genentech two fiveyear renewal options building option purchase various buildings different dates genentech also right first refusal respect building entire development slough consider selling part development december based status development date total carrying value property plant equipment agreement including tenant improvements million swiss francs million swiss francs carrying value leasing obligation million swiss francs million swiss francs estimates total future minimum lease payments anticipated entire master lease agreement shown estimated total future minimum lease payments slough leases millions chf total minimum principal ground lease interest lease payments within one year one five years five years total matters details genentech matters given following notes acquisition tanox note genentech legal cases note genentechs equity compensation plans note genentechs senior notes commercial paper program note chugai effective october roche group chugai completed alliance create leading researchdriven japanese pharmaceutical company formed merger chugai roches japanese pharmaceuticals subsidiary nippon roche merged company known chugai fully consolidated subsidiary group december groups interest chugai common stock chugai publicly traded listed tokyo stock exchange stock code tse chugai prepares financial statements conformity accounting principles generally accepted injapan jgaap filed quarterly basis tokyo stock exchange relationship chugai chugai entered certain agreements roche discussed basic alliance agreement part basic alliance agreement signed december roche chugai entered certain arrangements covering future operation governance chugai amongst matters cover following areas structuring alliance roches rights shareholder roches rights nominate members chugais board directors certain limitations roches ability buy sell chugais common stock finance report roche group notes roche group consolidated financial statements chugai issues additional shares common stock connection convertible debt equity compensation plans may issue additional shares purposes affects roches percentage ownership interest basic alliance agreement provides amongst matters chugai guarantee roches right maintain shareholding percentage chugai less licensing agreements japan umbrella rights agreement signed december chugai exclusive rights market roches pharmaceutical products japan chugai also first right refusal development marketing japan development compounds advanced roche rest world umbrella rights agreement signed may roche right first refusal development marketing chugais development compounds markets outside japan excluding south korea chugai decides requires partner activities agreements roche chugai signed series separate agreements certain specific products depending specific circumstances terms agreement may result payments armslength basis roche chugai following matters upfront payments right first refusal license product exercised milestone payments dependent upon achievement agreed performance targets royalties future product sales specific product agreements may also cover manufacture supply respective products meet partys clinical andor commercial requirements armslength basis research collaboration agreementsroche chugai entered research collaboration agreements areas small molecule synthetic drug research biotechnology based drug discovery differences ifrs jgaap due certain consolidation entries differences requirements international financial reporting standards ifrs jgaap differences chugais standalone financial results jgaap basis financial results chugai consolidated roche group accordance ifrs acquisition roche interest chugai treated business combination ifrs jgaap alliance treated merger chugai nippon roche therefore jgaap results chugai include goodwill fair value adjustments recorded roches results quantified table moreover acquisition accounting includes roches fair value adjustments therefore impact net income needs added back minority interest calculations roches ifrs results roches ifrs results depreciation property plant equipment calculated using straightline method chugais jgaap results reducing balance method used additionally certain income expenses notably restructuring costs required jgaap reported extraordinary items inchugais jgaap results extraordinary items reported operating profit line roches ifrs results items normally included part operating profit treated extraordinary exceptional items restructuring costs million swiss francs million swiss francs differences ifrs jgaap relatively minor impact finance report roche group notes roche group consolidated financial statements reconciliation chugai results jpy chf jpy chf billions millions billions millions operating profit jgaap basis depreciation basis difference classification extraordinary items differences consolidation entries operating profit acquisition accounting impacts ifrs basis depreciation property plant equipment amortisation intangible assets arising business combinations operating profit ifrs basis add deduct corporate nonoperating items ifrs basis financial income financing costs income taxes net income ifrs basis minority interest calculation add back acquisition accounting impact net income net income excluding acquisition accounting minority interest percentage average year income applicable minority interest ifrs basis translated jpy chf jpy chf dividends dividends distributed third parties holding chugai shares totalled million swiss francs million swiss francs recorded minority interests see note dividends paid chugai roche eliminated consolidation intercompany items chugai share repurchases chugai repurchased million common shares total consideration billion japanese yen million swiss francs result groups ownership chugai increased share repurchases matters details chugais equity compensation plans given note details series chugai pharmaceutical unsecured convertible bonds including conversions year given note finance report roche group notes roche group consolidated financial statements financial income financing costs financial income millions chf year ended december gains sale equity securities losses sale equity securities dividend income gains losses equity derivatives net writedowns impairments equity securities net income equity securities interest income gains sale debt securities losses sale debt securities net gains losses financial assets fairvaluethroughprofitorloss writedowns impairments debt securities net interest income income debt securities expected return plan assets defined benefit plans foreign exchange gains losses net gains losses foreign currency derivatives net net foreign exchange gains losses net financial income expense total financial income financing costsin millions chf year ended december interest expense amortisation discount debt instruments gains losses interest rate derivatives net net gains losses financial liabilities fairvaluethroughprofitorloss time cost provisions interest cost defined benefit plans total financing costs net financial income millions chf year ended december financial income financing costs net financial income financial result treasury management financial result pension management net financial income finance report roche group notes roche group consolidated financial statements net gains losses financial liabilities fairvaluethroughprofitorloss includes change fair value attributable changes liabilities credit risk component calculated comparing difference present value future cash flows bonds discounted using swap yield curve based libor market prices bonds due widening credit spread relative swap yield curve change fair value attributable changes liabilities credit risk component gain million swiss francs zero cumulative change fair value attributable change credit risk since issuance instruments gain million swiss francs gain million swiss francs interest expense liabilities fairvaluethroughprofitorloss million swiss francs million swiss francs income taxes income tax expenses millions chf current income taxes adjustments recognised current tax prior periods deferred income taxes total charge income taxes since group operates internationally subject income taxes many different tax jurisdictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates rate changes year year due changes mix groups taxable income changes local tax rates rate reduced percentage points compared reduction mainly result relatively lower proportion groups pretax income arising tax jurisdictions higher tax rates together groups ongoing efforts optimise tax structure thegroups effective tax rate reconciled groups average expected tax rate follows reconciliation groups effective tax rate average expected tax rate tax effect utilisation previously unrecognised tax losses nontaxable incomenondeductible expenses genentech equity compensation plans differences groups effective tax rate income tax assets liabilities millions chf current income taxes assets liabilities net current income tax assets liabilities deferred income taxes assets liabilities net deferred income tax assets liabilities deferred income tax assets recognised tax loss carry forwards extent realisation related tax benefit probable group unrecognised tax losses including valuation allowances follows finance report roche group notes roche group consolidated financial statements unrecognised tax losses expiry millions chf applicable applicable amount tax rate amount tax rate within one year one five years five years total unrecognised tax losses deferred income tax liabilities established withholding tax taxes would payable unremitted earnings certain foreign subsidiaries amounts currently regarded permanently reinvested unremitted earnings totalled billion swiss francs december billion swiss francs deferred income tax assets liabilities deferred income tax charges credits attributable tothefollowing items deferred income taxes movements recognised net assets liabilities millions chf property plant equipment temporary intangible assets differences total year ended december net deferred income tax asset liability january charged credited income statement charged credited equity recognised gains losses charged credited equity equity compensation plans transactions shareholders currency translation effects net deferred income tax asset liability december year ended december net deferred income tax asset liability january bioveris acquisition tanox acquisition business combinations charged credited income statement charged credited equity recognised gains losses charged credited equity equity compensation plans transactions shareholders currency translation effects net deferred income tax asset liability december business combinations acquisitions bioveris effective june group acquired controlling interest bioveris corporation bioveris publicly owned us company listed nasdaq symbol biov bioveris healthcare biosecurity company based gaithersburg maryland specialises developing proprietary technologies diagnostics bioveris reported part diagnostics operating segment purchase consideration million swiss francs consisted million swiss francs cash million swiss francs directly attributable costs allocated follows finance report roche group notes roche group consolidated financial statements bioveris acquisition net assets acquired millions chf carrying value fair value carrying value prior acquisition adjustments upon acquisition property plant equipment intangible assets product intangibles use deferred income taxes cash net assets liabilities net identifiable assets liabilities goodwill purchase consideration goodwill represents assets recognised separately measured reliably synergies obtained groups existing electrochemiluminescence ecl immunochemistry business also represents premium paid traded market price obtain control business following acquisition restructuring expenses million swiss francs incurred reported within operating result diagnostics division tanoxeffective august genentech acquired controlling interest tanox inc tanox publicly owned us company listed nasdaq symbol tnox tanox biotechnology company based houston texas specialises discovery development biotherapeutics based monoclonal antibody technology genentech tanox working together collaboration novartis since develop commercialise xolair purchase consideration million swiss francs consisted million swiss francs cash million swiss francs directly attributable costs allocated follows tanox acquisition net assets acquired millions chf carrying value fair value carrying value prior acquisition adjustments upon acquisition property plant equipment intangible assets product intangibles use product intangibles available use deferred income taxes cash marketable securities net assets liabilities net identifiable assets liabilities goodwill purchase consideration goodwill represents assets recognised separately measured reliably earlystage research projects also represents premium paid traded market price obtain control business acquisitions effective march group acquired controlling interest therapeutic human polyclonals inc thp privately owned us biotechnology company based california germany thp reported part roche pharmaceuticals operating segment purchase consideration paid million swiss francs cash finance report roche group notes roche group consolidated financial statements effective may group acquired controlling interest life sciences majorityowned us subsidiary curagen corporation life sciences develops commercialises novel instrumentation forhighthroughput dna sequencing based branford connecticut life sciences reported part diagnostics operating segment purchase consideration paid million swiss francs cash consisted million swiss francs cash million swiss francs directly attributable costs effective august group acquired controlling interest nimblegen systems inc nimblegen privately owned us company nimblegen develops commercialises high density dna microarrays based madison wisconsin nimblegen reported part diagnostics operating segment purchase consideration million swiss francs cash minor business combinations total purchase consideration million swiss francs combined purchase consideration acquisitions allocated shown acquisitions net assets acquired millions chf carrying value fair value carrying value prior acquisition adjustments upon acquisition property plant equipment intangible assets product intangibles use product intangibles available use technology intangibles deferred income taxes cash net assets liabilities net identifiable assets liabilities goodwill purchase consideration goodwill represents assets recognised separately measured reliably earlystage research projects control premium synergies obtained groups existing business acquisitions impact results millions chf revenues amortisation operating external customers intangible assets profit net income impact reported results tanox thp minor acquisitions pharmaceuticals division bioverisa life sciences nimblegen diagnostics division group figures exclude restructuring expenses million swiss francs related bioveris finance report roche group notes roche group consolidated financial statements revenues amortisation operating external customers intangible assets profit net income estimated impact results acquisition assumed effective january tanox thp minor acquisitions pharmaceuticals division bioverisa life sciences nimblegen diagnostics division group figures exclude restructuring expenses million swiss francs related bioveris acquisitions net cash outflow millions chf cash cash acquired net cash consideration paid company outflow bioveris tanox acquisitions total future acquisitions ventana january group announced entered agreement acquire controlling interest ventana medical systems inc ventana publicly owned us company listed nasdaq symbol vmsi ventana develops manufactures markets instrumentreagent systems automate slide preparation staining clinical histology drug discovery laboratories ventanas clinical systems used diagnosis treatment cancer infectious diseases drug discovery systems used pharmaceutical biotechnology companies accelerate discovery new drug targets evaluate safety new drug compounds ventana based tucson arizona transaction completed ventana reported part diagnostics operating segment tender offer usd per share expiring february subject amongst matters conditions validly tendered withdrawn number common shares together shares owned group represents majority total number common shares outstanding fullydiluted basis completed overall purchase consideration excluding transaction costs would approximately billion us dollars cash would provided groups cash hand time ofclosing transaction expected completed first half acquisitions acquisitions subsidiaries associated companies discontinued businesses group completed sale vitamins fine chemicals business vfc business dutch company dsm sale roche consumer health global otc overthecounter medicines business bayer group december business transfers made allpurchase consideration received calculations final amounts arising agreed purchase price mechanisms completed resulting cash transfers made finance report roche group notes roche group consolidated financial statements accordingly effective january groups management concluded remaining residual balances transactions considered part groups continuing businesses reported corporate segment january balances consisted provisions noncurrent liabilities totalling million swiss francs primarily relate indemnities guarantees respect litigation environmental matters impact result corporate segment income million swiss francs relating release certain accruals longer required results include million swiss francs profit discontinued businesses consisted income million swiss francs relating release certain accruals provisions longer required less million swiss francs expenses unwinding discounted provisions million swiss francs income tax expenses impact chf earnings per share nonvoting equity security basic diluted employee benefits employee remuneration millions chf wages salaries social security costs defined contribution postemployment plans operating expenses defined benefit postemployment plans equity compensation plans employee benefits employees remuneration included operating results expected return plan assets defined benefit postemployment plans interest cost defined benefit postemployment plans total employees remuneration employee benefits consist mainly life insurance schemes certain insurance schemes providing medical coverage longterm shortterm disability benefits charges employee benefits operating results included relevant expenditure line function expected return plan assets interest costs defined benefit plans included part financial income financing costs respectively see note pensions postemployment benefits groups objective provide attractive competitive postemployment benefits employees atthe time ensuring various plans appropriately financed managing potential impacts groups longterm financial position employees covered pension plans sponsored group companies nature plans varies according legal regulations fiscal requirements economic conditions countries employees employed postemployment benefits consist mostly postretirement healthcare life insurance schemes principally united states postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation topay contributions plans classified defined benefit plans even groups potential obligation relatively minor relatively remote possibility arising consequently groups postemployment benefit plans classified defined benefit plans purpose financial statements finance report roche group notes roche group consolidated financial statements defined contribution plans defined contribution plans typically consist payments employees group funds administered third parties payments group million swiss francs million swiss francs assets liabilities recognised groups balance sheet respect plans apart regular prepayments accruals contributions withheld employees wages salaries groups contributions defined benefit plans groups major defined benefit plans located switzerland united states germany united kingdom japan plans usually established trusts independent group funded payments group employees cases notably major defined benefit plans germany plan unfunded group pays pensions retired employees directly financial resources current past service costs charged appropriate income statement heading within operating results pension plan administration funding overseen corporate level settlement gains losses resulting changes funding arrangements reported general administration expenseswithin corporate segment expected returns plan assets interest costs charged financial income financing costs respectively actuarial gains losses recorded directly equity recognition pension assets limited total present value future refunds plans reductions future contributions plans cumulative unrecognised past service costs adjustments arising limit recognition assets defined benefit plans recorded directly inequity defined benefit plans expenses millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total current service cost past service cost gain loss curtailment gain loss settlement total operating expenses expected return plan assets interest cost total financial income expense total expense recognised income statement funding groups various defined benefit plans overseen corporate level qualified independent actuaries carry valuations regular basis major plans annually balance sheet date funded plans usually trusts independent groups finances net assetliability recognised groups balance sheet corresponds overunder funding plan adjusted unrecognised past service costs unfunded plans group meets pension obligations directly financial resources liability defined benefit obligation recorded groups balance sheet pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan amounts recognised balance sheet postemployment benefits predominantly noncurrent reported noncurrent assets liabilities finance report roche group notes roche group consolidated financial statements defined benefit plans funding status december millions chf funded unfunded funded unfunded plans plans total plans plans total fair value plan assets defined benefit obligation funding unrecognised past service costs limit asset recognition reimbursement rights net recognised asset liability reported defined benefit plans reimbursement rights postemployment benefit assets postemployment benefit liabilities net recognised asset liability detailed information plan assets defined benefit obligation given defined benefit plans fair value plan assets reimbursement rights millions chf fair fair value reim value reim plan bursement plan bursement assets rights total assets rights total january expected return plan assets actuarial gains losses currency translation effects employer contributions employee contributions benefits paid funded plans past service cost business combinations curtailments settlements december invested shares equity instruments bonds debentures debt instruments property assets total included within fair value plan assets thousand groups nonvoting equity securities fair value million swiss francs thousand nonvoting equity securities total fair value ofmillion swiss francs finance report roche group notes roche group consolidated financial statements defined benefit plans defined benefit obligation millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january current service cost interest cost employee contributions actuarial gains losses currency translation effects benefits paid funded plans benefits paid unfunded plans past service cost business combinations curtailments settlements december funded plans unfunded plans actuarial assumptions actuarial assumptions unbiased mutually compatible estimates variables determine ultimate cost providing postemployment benefits set annual basis local management actuaries subject approval corporate management groups actuaries actuarial assumptions consist demographic assumptions matters mortality employee turnover financial assumptions onmatters salary benefit levels interest rates return investments costs medical benefits group operates defined benefit plans many countries actuarial assumptions vary based upon local economic social conditions demographic assumptions significant demographic assumptions relate mortality rates groups actuaries use mortality tables take account historic patterns expected changes asfurther increases longevity mortality tables used major schemes germany heubeck tables g japan national census life table switzerland bvg united kingdom nonpensioners pac rated one year united kingdom pensioners pac rated one year united states rp projected rates employee turnover disability early retirement based historical behaviour within group companies financial assumptions based market expectations period obligations aretobe settled ranges assumptions used actuarial valuations significant plans countries stable currencies interest rates shown finance report roche group notes roche group consolidated financial statements defined benefit plans financial actuarial assumptions weighted weighted average range average range discount rates expected rates return plan assets expected rates salary increases medical cost trend rate discount rates used calculate discounted present value defined benefit obligation determined reference market yields high quality corporate bonds government bonds countries deep market corporate bonds currency term bonds consistent theobligation discounted interest cost included income statement calculated multiplying discount rate defined benefit obligation expected returns plan assets based market expectations expected returns assets funded plans duration related obligation takes account split plan assets equities bonds property investments calculation includes assumptions concerning expected dividend interest income realised unrealised gains plan assets taxes administration costs borne plan based longterm market expectations actual performance continually monitored corporate management due longterm nature obligations assumptions used matters returns investments may necessarily consistent recent historical patterns expected return plan assets included income statement calculated multiplying expected rate return fair value plan assets difference expected return actual return twelve month period actuarial gainloss recorded directly equity actual return plan assets million swiss francs million swiss francs expected rates salary increases used calculate defined benefit obligation current service cost included income statement based latest expectation historical behaviour within group companies medical cost trend rates used calculate defined benefit obligation current service cost included income statement postemployment medical plans take account benefits set plan terms expected future changes medical costs since groups major postemployment medical plans us employees rates driven developments united states effect one percentage point increase decrease medical cost trend rate shown defined benefit plans sensitivity medical cost trend ratein millions chf current service cost interest cost defined benefit obligation funding summary fiveyear summary funding status groups defined benefit plans shown table finance report roche group notes roche group consolidated financial statements defined benefit plans summary funding status millions chf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation increase decrease funding status arising experience adjustments fair value plan assets defined benefit obligation increase decrease funding status arising changes actuarial assumptions fair value plan assets defined benefit obligation cash flows group incurred cash flows defined benefit plans shown table defined benefit plans cash flows millions chf employer contributions funded plans benefits paid unfunded plans total cash inflow outflow based recent actuarial valuations group expects employer contributions funded plans approximately million swiss francs benefits paid unfunded plans approximately million swiss francs amounts recorded equity actuarial gains losses recognised statement recognised income expense gains million swiss francs gains million swiss francs total amount december accumulated gains million swiss francs gains million swiss francs addition recognition pension assets limited total present value future refunds plans reductions future contributions plans cumulative unrecognised past service costs adjustments arising limit asset recognition recorded directly equity adjustment million swiss francs million swiss francs employee stock options equity compensation benefits group operates several equity compensation plans including separate plans genentech chugai effective january group adopted ifrs sharebased payment amongst matters standard requires fair value equity compensation plan awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading finance report roche group notes roche group consolidated financial statements expenses equity compensation plans millions chf cost sales marketing distribution research development general administration total operating expense share option plans roche option plan genentech stock option plan chugai stock acquisition rights total share option plans equity compensation plans roche connect genentech employee stock purchase program roche stocksettled stock appreciation rights roche performance share plan roche stock appreciation rights total equity compensation plans total operating expense equitysettled cashsettled cash inflow outflow equity compensation plans millions chf share option plans roche option plan genentech stock option plan chugai stock acquisition rights total share option plans equity compensation plans roche connect genentech employee stock purchase program roche stocksettled stock appreciation rights roche performance share plan roche stock appreciation rights total equity compensation plans total cash inflow outflow equitysettled cashsettled roche longterm group implemented new global longterm incentive programme available certain directors management employees selected discretion group programme consists stocksettled stock appreciation rights ssars group alternative granting awards existing roche option plan finance report roche group notes roche group consolidated financial statements share option plans roche option planawards plan give employees right purchase nonvoting equity securities exercise price specified grant date options nontradable equitysettled awards sevenyear duration vest phased basis three years subject continued employment group covers obligations purchasing nonvoting equity securities derivatives thereon see note introduction roche longterm number options granted roche option plan significantly reduced eligible employees receive roche stocksettled stock appreciation rights instead roche option plan movement number options outstanding number weighted average number weighted average options exercise price options exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche option plan terms options outstanding december options outstanding options exercisable weighted weighted number weighted average average number average outstanding years remaining exercise exercisable exercise year grant thousands contractual life price chf thousands price chf total genentech stock option planthe genentech stock option plan adopted amended thereafter april genentechs shareholders approved equity incentive plan plans allow granting various stock options incentive stock options stock purchase rights employees directors consultants genentech incentive stock options stock purchase rights granted plan date options granted nontradable equitysettled awards tenyear duration vest phased basis four years subject continued employment genentech stock option plan movement number options outstanding number number options weighted average options weighted average millions exercise price usd millions exercise price usd outstanding january granted forfeited exercised expired outstanding december exercisable finance report roche group notes roche group consolidated financial statements genentech stock option plan terms options outstanding december options outstanding options exercisable weighted weighted number weighted average average number average range exercise prices outstanding years remaining exercise exercisable exercise usd millions contractual life price usd millions price usd total chugai stock acquisition rights chugai adopted stock acquisition rights programme programme allows granting rights employees directors chugai right entitles holder purchase chugai shares specified exercise price options nontradable equitysettled awards tenyear duration vest two years chugai stock acquisition rights movement number rights outstanding number weighted average number weighted average options exercise price jpy options exercise price jpy outstanding january granted forfeited exercised expired outstanding december exercisable chugai stock acquisition rights terms rights outstanding december rights outstanding rights exercisable weighted weighted weighted average average average number years remaining exercise number exercise year grant outstanding contractual life price jpy exercisable price jpy total issues share options issues share options including methodology used calculate fair value main inputs valuation models described finance report roche group notes roche group consolidated financial statements issues share option plans roche genentech stock chugai stock option plan option plan acquisition rights number options granted thousand million underlying equity roche nonvoting genentech common chugai shares equity securities stock blocks currency swiss francs us dollars japanese yen vesting period progressively progressively years years years contractual life years years years weighted average fair value options issued option pricing model used binomial binomial binomial inputs option pricing model share price grant date exercise price expected volatility expected dividend yield early exercise factor na expected exit rate volatility roche chugai options determined primarily reference historically observed prices underlying equity volatility genentech options determined primarily reference implied volatility genentechs traded options riskfree interest rates derived zero coupon swap rates grant date taken datastream early exercise factor describes ratio expected market price exercise date exercise price early exercises expected based historically observed behaviour chugai grants assumed awards would held full term length since insufficient historically observed early exercise behaviour equity compensation plans roche connect programme enables employees worldwide except united states certain countries make regular deductions salaries purchase nonvoting equity securities administered independent third parties group contributes programme allows employees purchase nonvoting equity securities discount usually administrator purchases thenecessary nonvoting equity securities directly market december administrator held thousand nonvoting equity securities thousand programme operational since october year cost plan million swiss francs million swiss francs reported within relevant expenditure line function genentech employee stock purchase program espp genentech employee stock purchase programme allows employees purchase genentechs common stock lower market value grant date purchase date total million shares genentech common stock purchased million shares resulting cash inflow million swiss francs million swiss francs year cost plan million swiss francs million swiss francs reported within relevant expenditure line function roche stocksettled stock appreciation rightswith introduction roche longterm group offers stocksettled stock appreciation rights ssars certain directors management employees selected discretion group ssars give employees right receive nonvoting equity securities reflecting value appreciation market price nonvoting equity securities grant date exercise date options nontradable equitysettled awards seven year duration vest phased basis three years subject continued employment group covers obligations purchasing nonvoting equity securities derivatives thereon see note finance report roche group notes roche group consolidated financial statements roche ssars movement number rights outstanding number number rights weighted average rights weighted average thousands exercise price chf thousands exercise price chf outstanding january granted forfeited exercised expired outstanding december exercisable roche ssars terms rights outstanding december rights outstanding rights exercisable weighted weighted number weighted average average number average outstanding years remaining exercise exercisable exercise year grant thousands contractual life price chf thousands price chf total weighted average fair value options granted calculated using binomial model inputs model consistent used roche option plan awards given previously resulting weighted average fair value per right chf giving total fair value million swiss francs charged vesting period three years roche performance share plan group offers future nonvoting equity security awards discretion board directors cash equivalent certain directors key senior managers programme established beginning effect three years board directors approved new threeyear cycle roche performance share plan psp operate amount nonvoting equity securities allocated depend upon individuals salary level achievement performance targets linked groups total shareholder return shares nonvoting equity securities combined relative groups peers threeyear period date grant discretion board directors nontradable equitysettled awards award result zero two nonvoting equity securities depending upon achievement performance targets additional cycles psp similar conditions approved operate terms awards set table roche performance share plan terms awards number awards thousands vesting period years years years allocated recipients feb feb feb fair value per unit chf total fair value chf millions weighted average fair value awards granted calculated using monte carlo simulation input parameters model covariance matrix roche individual companies peer group based threeyear history riskfree rate valuation also takes account defined rank performance structure determines payout psp finance report roche group notes roche group consolidated financial statements roche stock appreciation rights employees certain north american subsidiaries group receive stock appreciation rights sars part compensation sars nontradable cash settled awards may exercised vesting period one three years cash payment based upon amount market price groups american depositary receipts adrs point ofexercise exceeds strike price grant price issuance following implementation roche longterm see group plan award cashsettled sars awards made since roche stock appreciation rights millions chf liability december intrinsic value vested rights december roche stock appreciation rights terms rights outstanding december rights outstanding exercisable number outstanding weighted average exercisable exercise year grant thousands expiry price usd jul dec feb feb total fair value december calculated using binomial model inputs model adr price december usd exercise prices given table inputs consistent used roche option plan awards given previously property plant equipment property plant equipment movements carrying value assets millions chf buildings land machinery improve construction land ments equipment progress total january cost accumulated depreciation impairment net book value year ended december january additions disposals divestment genentech espaa transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value finance report roche group notes roche group consolidated financial statements buildings land machinery improve construction land ments equipment progress total year ended december january additions disposals bioveris acquisition tanox acquisition business combinations transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors changes planned use buildings machinery orequipment closure facilities presence absence competition technical obsolescence could result shortened useful lives impairment impairment charges million swiss francs million swiss francs reported part cost sales leasing arrangements group lessee finance leases december capitalised cost property plant equipment finance leases million swiss francs million swiss francs net book value assets wasmillion swiss francs million swiss francs finance leases future minimum lease payments noncancellable leasesin millions chf future minimum lease present value future payments minimum lease payments within one year one five years five years total future finance charges total future minimum lease payments undiscounted addition genentech leasing arrangements disclosed note operating leasesgroup companies party number operating leases mainly plant machinery including motor vehicles certain shortterm property rentals arrangements impose significant restrictions group total operating lease rental expense million swiss francs million swiss francs finance report roche group notes roche group consolidated financial statements operating leases future minimum lease payments noncancellable leases millions chf within one year one five years five years total minimum payments leasing arrangements group lessor finance leasescertain assets mainly diagnostics instruments leased third parties finance lease arrangements assets reported receivables amount equal net investment lease lease income finance leases recognised term lease based effective interest rate method finance leases future minimum lease payments noncancellable leases millions chf present value future gross investment lease minimum lease payments within one year one five years five years total unearned finance income na na unguaranteed residual value na na net investment lease accumulated allowance uncollectible minimum lease payments million swiss francs million swiss francs contingent rents recognised income operating leases certain assets mainly diagnostics instruments leased third parties operating lease arrangements assets reported within property plant equipment lease income fromoperating leases recognised lease term straight line basis operating leases future minimum lease payments noncancellable leases millions chf within one year one five years five years total minimum payments december machinery equipment original cost million swiss francs mil lion swiss francs net book value million swiss francs million swiss francs leased third parties contingent rent recognised income capital commitments group noncancellable capital commitments purchase construction property plant equipment totalling billion swiss francs billion swiss francs addition genentechs capital commitments respect manufacturing agreements lonza leasing arrangements described note finance report roche group notes roche group consolidated financial statements goodwill goodwill movements carrying value assetsin millions chf january bioveris acquisition tanox acquisition business combinations impairment charge currency translation effects december allocated following cashgenerating units pharmaceuticals division roche pharmaceuticals genentech chugai total pharmaceuticals division diagnostics division diabetes care professional diagnostics molecular diagnostics applied science corangeboehringer mannheim held divisional level allocated business areas total diagnostics division total group accumulated impairment losses goodwill goodwill arising investments associated companies classified part investments associated companies see note goodwill impairment testing pharmaceuticals divisionthe divisions reportable operating segments cashgenerating units used testing goodwill genentech chugai recoverable amount based fair value less costs sell determined reference publicly quoted share prices genentech chugai shares goodwill roche pharmaceuticals significant comparison groups total carrying amount goodwill diagnostics division divisions business areas cashgenerating units used testing goodwill goodwill arising corangeboehringer mannheim acquisition recorded monitored divisional level meaningfully allocated divisions business areas therefore cash generating unit goodwill entire division recoverable amount used impairment testing based value use cash flow projections used based recent business plans approved management assume significant changes organisation division include managements latest estimates sales volume pricing production operating costs reflect past experience projected five years discount rate used based rate derived capital asset pricing model using data swiss capital markets including swiss federal government tenyear bonds swiss market index adjusted pretax rate management believes reasonably possible change key assumptions would cause carrying value goodwill exceed recoverable amount finance report roche group notes roche group consolidated financial statements intangible assets intangible assets movements carrying value assetsin millions chf product product intangibles intangibles available technology use use intangibles total january cost accumulated amortisation impairment net book value year ended december january additions disposals amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value year ended december january bioveris acquisition tanox acquisition business combinations additions disposals amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocation operating segment roche pharmaceuticals genentech chugai diagnostics total group finance report roche group notes roche group consolidated financial statements significant intangible assets december millions chf operating net book remaining segment value amortisation period product intangibles use tanox acquisition genentech years chugai acquisition chugai years corangeboehringer mannheim acquisition diagnostics years igen acquisition diagnostics years product intangibles available use alnylam alliance roche pharmaceuticals na classification amortisation impairment expenses millions chf amortisation impairment amortisation impairment cost sales pharmaceuticals diagnostics research development pharmaceuticals diagnostics total internally generated intangible assets group currently internally generated intangible assets development criteria recognition asset met impairment intangible assets impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors presence absence competition technical obsolescence lower anticipated sales products capitalised rights could result shortened useful lives impairment genentech operating segment impairment charge million swiss francs recorded second half relates decision terminate development compounds two alliance partners roche pharmaceuticals operating segment impairment charge million swiss francs recorded first half relates decision terminate development one compound analliance partner assets concerned yet amortised fully writtendown charges second half group recorded impairment charges million swiss francs relating intangible assets diagnostics division followed regular updating divisions business plans technology assessments second half indicated anticipated recoverable amounts current carrying values certain assets mainly concern certain intangible assets recorded following disetronic acquisition assets written recoverable amount based value use calculation using discount rate additionally remaining useful life assets reassessed reduced years years effective december consequent matters amortisation charge intangible assets diagnostics division approximately million swiss francs lower would otherwise roche pharmaceuticals operating segment impairment charge million swiss francs recorded second half relates decision terminate development one compound alliance partner asset concerned yet amortised fully writtendown charge intangible assets yet available use mostly represent inprocess research development assets pharmaceuticals division acquired either inlicensing arrangements business combinations separate purchases december carrying value assets pharmaceuticals division million swiss francs amount approximately represents projects potential decision finance report roche group notes roche group consolidated financial statements points within next twelve months certain circumstances could lead impairment due inherent uncertainties research development process assets particularly risk impairment project question result commercialised product potential commitments alliance collaborations group party inlicensing similar arrangements alliance partners arrangements may require group make certain milestone similar payments dependent upon achievement agreed objectives performance targets defined collaboration agreements groups current estimate future thirdparty commitments payments set table figures risk adjusted meaning include potential payments arise assuming projects currently development successful timing based groups current best estimate figures include potential commitments within group may arise roche pharmaceuticals genentech chugai businesses potential future thirdparty collaboration payments millions chf pharmaceuticals diagnostics group within one year one two years two three years total associated companies groups investments associated companies accounted using equity method goodwill arising investments associated companies classified part investments associated companies investments associated companies millions chf share net income balance sheet value total investments associated companies group significant investments associated companies material transactions group associated companies additional information associated companies given innote financial longterm assets financial longterm assetsin millions chf availableforsale investments heldtomaturity investments loans receivable longterm trade receivables restricted cash total financial longterm assets prepaid employee benefits total longterm assets financial longterm assets held strategic purposes classified noncurrent availablefor sale investments mainly equity investments unquoted equity investments classified availableforsale generally measured cost fair value measured reliably primarily investments finance report roche group notes roche group consolidated financial statements inprivate biotechnology companies kept part groups strategic alliance efforts carrying value equity investments held cost million swiss francs million swiss francs average effective interest rate heldtomaturity investments loans receivable comprise loans third parties term one year restricted cash includes million swiss francs surety bond posted genentech connection city hope litigation see note equivalent amount classified current assets see note inventories inventories millions chf raw materials supplies work process finished goods intermediates less provision slowmoving obsolete inventory total inventories expenses relating inventories expensed cost sales totalled million swiss francs million swiss francs accounts receivable accounts receivablein millions chf trade accounts receivable notes receivable less allowances total accounts receivable december accounts receivable include amounts denominated us dollars equivalent billion swiss francs billion swiss francs amounts denominated euros equivalent billion swiss francs billion swiss francs net bad debt expense million swiss francs following recovery previously provided amounts group recorded net income bad debts million swiss francs significant concentrations within trade receivables counterparty credit risk described note current assets current assetsin millions chf accrued interest income derivative financial instruments restricted cash total financial current assets prepaid expenses total nonfinancial current assets total current assets restricted cash includes million swiss francs surety bond posted genentech connection city hope litigation see note equivalent amount classified within financial long term assets see note finance report roche group notes roche group consolidated financial statements marketable securities marketable securitiesin millions chf financial assets fairvaluethroughprofitorloss heldfortrading investments bonds debentures designated fairvaluethroughprofitorloss bonds debentures money market instruments time accounts three months investments total financial assets fairvaluethroughprofitorloss availableforsale financial assets shares bonds debentures money market instruments time accounts three months investments total availableforsale financial assets total marketable securities marketable securities held fund management purposes classified current primarily denominated swiss francs euros us dollars investments held strategic purposes classified noncurrent see note sharesthese consist primarily readily saleable equity securities bonds debentures carrying amounts contract maturity average effective interest rate debt securities shown bonds debentures millions chf average effective average effective contracted maturity amount interest rate amount interest rate within one year one five years five years total bonds debentures money market instruments generally fixed interest rates ranging depending upon currency denominated contracted mature within one year december cash cash equivalents cash cash equivalentsin millions chf cash cash hand current call accounts cash equivalents time accounts maturity three months less total cash cash equivalents restricted cash included within financial longterm assets see note current assets seenote finance report roche group notes roche group consolidated financial statements accounts payable accounts payablein millions chf trade accounts payable taxes payable accounts payable total accounts payable accrued current liabilities accrued current liabilitiesin millions chf deferred income accrued payroll related items interest payable derivative financial instruments accrued liabilities total accrued current liabilities derivative financial instruments appropriate circumstances group uses derivative financial instruments part risk management trading strategies discussed note derivative financial instruments carried fair value themethods used determining fair value described note derivative financial instrumentsin millions chf assets liabilities foreign currency derivatives forward exchange contracts swaps interest rate derivatives swaps derivatives total derivative financial instruments hedge accounting groups accounting policy hedge accounting described note requires qualify hedge accounting hedging relationship must meet several strict conditions documentation probability ofoccurrence hedge effectiveness reliability measurement described note group financial risk management policies foreign exchange risk interest rate risk market risk credit risk liquidity risk deemed appropriate certain risks managed use derivatives many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income finance report roche group notes roche group consolidated financial statements group generally limits use hedge accounting certain significant transactions consequently december group fair value hedges cash flow hedges hedges net investment foreign entity meet strict requirements qualify hedge accounting apart described genentech hedged fixedterm debt instruments interest rate swaps december instruments designated qualify fair value hedges recorded balance sheet asset fair value million swiss francs liability million swiss francs genentech nonus dollar cash flows future royalty income development expenses expected next one five years hedge part foreign exchange risk genentech enters derivative financial instruments options forward contracts genentech equity investments various biotechnology companies subject greater risk market fluctuation stock market general manage part exposure genentech enters derivative financial instruments zero cost collars forward contracts december instruments designated qualify hedge accounting recorded assets fair value million swiss francs assets million swiss francs liabilities million swiss francs matters also described genentechs annual report quarterly sec filings movements fair value reserve designated cash flow hedges included note provisions contingent liabilities provisions movements recognised liabilities millions chf legal environmental restructuring provisions provisions provisions provisions total year ended december january additional provisions created unused amounts reversed utilised year unwinding discount currency translation effects december current portion noncurrent portion total provisions year ended december january additional provisions created unused amounts reversed utilised year unwinding discount currency translation effects december current portion noncurrent portion total provisions finance report roche group notes roche group consolidated financial statements legal environmental restructuring provisions provisions provisions provisions total expected outflow resources within one year one two years two three years three years total provisions legal provisions legal provisions relate mainly number major legal cases described amounts timing uncertainties outflows discussed discount rates used remaining legal provisions account less balance consist number separate legal matters various group companies majority cash outflows matters expected occur within next one three years although dependent development various litigations provisions discounted time value money material matters environmental provisions provisions environmental matters include various separate environmental issues number countries nature amounts timing outflows difficult predict estimated timings cash outflows shown table significant provisions discounted time value money material restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed restructuring associated recurring activities group timings cash outflows reasonably certain global basis shown table significant provisions discounted time value money material provisions provisions consist mostly claims arising trade sales returns certain employee benefit obligations various provisions group companies fit categories timings cash outflows nature uncertain best estimates shown table significant provisions discounted time value money material contingent liabilities operations earnings group continue time time varying degrees affected bypolitical legislative fiscal regulatory developments including relating environmental protection countries operates industries group operates also subject risks various kinds nature frequency developments events covered byinsurance well effect future operations earnings predictable group entered strategic alliances various companies order gain access potential new products utilise companies help develop groups potential new products potential future payments may become due certain collaboration partners achieving certain milestones defined collaboration agreements groups best estimates future commitments payments given note finance report roche group notes roche group consolidated financial statements roche pharmaceuticals legal cases roche diagnostics gmbh rdg smithkline beecham cork ltd sb party arbitration concerning rdgs termination carvedilol license agreement amended relating licensing comarketing carvedilol rdg submitted two claims damages two arbitration tribunals zurich sb submitted counterclaim asserting invalidity rdgs termination claiming damages based development arbitration settlement negotiations time group increased existing provisions million swiss francs february group announced settlement agreement reached glaxosmithkline gsk settle arbitration procedures two companies relating licensing comarketing carvedilol part agreement group made payment gsk settlement impact groups net income payment wascovered previously recorded provisions surplus provisions released income genentech legal cases june genentech announced los angeles county superior court jury voted award city hope medical center city hope approximately million us dollars compensatory damages based finding breach agreement genentech city hope june jury voted award city hope million us dollars punitive damages case september genentech filed notice appeal jury verdict damages awards california court appeal october court appeal affirmed verdict damages awards respects also october genentech announced would seek review california supreme court discretion cases review november genentech filed petition review california supreme court february california supreme court granted petition appeal california supreme court fully briefed hearing set february amount cash paid timing payment depend decision california supreme court expected issued within ninety days hearing full provision totalling million swiss francs recorded awards reported current liability resolution expected within one year appeals process interest accrues total amount damages simple annual rate interest million swiss francs million swiss francs recorded time cost provisions within interest expenses october genentech entered arrangement thirdparty insurance companies post surety bond connection judgment part arrangement genentech pledged million us dollars cash investments secure bond amount equivalent million swiss francs december recorded restricted cash within current assets see note october genentech received subpoena united states department justice requesting documents related promotion rituxan genentech cooperating associated investigation genentech advised civil criminal nature government called may continue call former current genentech employees appear grand jury connection investigation outcome matter determined time april medimmune inc medimmune filed lawsuit genentech city hope national medical center celltech rd ltd us district court central district california los angeles lawsuit relates us patent cabilly patent coowned genentech city hope national medical center medimmune companies licensed paying royalties lawsuit includes claims violation antitrust patent unfair competition laws onjanuary us district court granted summary judgement medimmunes antitrust unfair competition claims april district court granted motion dismiss remaining claims inthis case october us court appeals federal circuit affirmed judgement district court respects january us supreme court issued decision reversing federal circuits decision remanding case lower courts proceedings connection patent contract claims august us district court entered claim construction order defining several terms used cabilly patent discovery motion practice ongoing trial matter scheduled june provisions recorded respect litigation outcome matter determined time finance report roche group notes roche group consolidated financial statements may request filed third party reexamination cabilly patent july us patent trademark office ordered reexamination patent september patent office issued initial nonfinal office action rejecting claims patent genentech filed response november second reexamination request patent filed december another third party january patent office granted reexamination request june two reexaminations combined patent office single reexamination august patent office issued nonfinal office action merged proceeding rejecting claims cabilly patent based issues raised two reexamination requests genentech filed response october february patent office mailed final office action rejecting thirty six claims cabilly patent may genentech responded final office action petitioned continued reexamination may patent office granted genentechs petition withdrew finality february office action agreed treat genentechs may filing response first office action cabilly patent expires relates methods used genentech others make certain antibodies antibody fragments well cells dna used methods genentech licensed cabilly patent companies derives significant royalties licences claims cabilly patent remain valid enforceable throughout reexamination process provisions recorded respect litigation outcome matter determined time july former genentech employee whose employment ended april filed nonpublic qui tam complaint seal united states district court district maine genentech biogen idec alleging violations false claims act retaliatory discharge employment december united states filed notice election decline intervention lawsuit complaint subsequently unsealed genentech served january genentech filed motion dismiss complaint december magistrate judge issued recommended decision motion subject review district court judge magistrate judge recommended false claims act portion complaint dismissed leaving remaining claim genentech plaintiffs retaliatory discharge claim plaintiff genentech biogen idec subsequently filed objections district court judge concerning certain aspects magistrate judges recommended decision july district court judge affirmed dismissal claims related false claims act denied genentechs motion dismiss plaintiffs federal retaliatory discharge claim granted plaintiffs motion leave file second amended complaint asserting additional state law employment claim provisions recorded respect litigation outcome matter determined time march mr kourosh dastgheib filed lawsuit genentech us district court eastern district pennsylvania lawsuit relates dastgheibs claim based relationship genentech mids entitled profits proceeds genentechs lucentis product november unanimous jury ruled dastgheib favour genentech claims final judgement entered genentechs favour january dastgheibs motion new trial denied entirety dastgheib appeal judgement court appeals accordingly case closed genentechs annual report quarterly sec filings contain detailed disclosures litigation matters required us gaap include details matters well including information litigation currently significant matters referred finance report roche group notes roche group consolidated financial statements noncurrent liabilities noncurrent liabilities millions chf deferred income longterm liabilities total noncurrent liabilities debt debt recognised liabilities millions chf debt instruments amounts due banks financial institutions genentech leasing obligations finance lease obligations borrowings total debt reported longterm debt shortterm debt total debt debt repayment terms millions chf within one year one two years two three years three four years four five years five years total debt fair value debt instruments billion swiss francs billion swiss francs fair value total debt billion swiss francs billion swiss francs calculated based observable market prices debt instruments present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows maturity periods pledges groups assets connection debt amounts due banks financial institutions amounts denominated various currencies notably euros average interest rate average interest rate balance primarily denominated canadian dollars swiss francs south african rand brazilian real repayment dates five years million swiss francs million swiss francs due within one year finance report roche group notes roche group consolidated financial statements debt instruments recognised liabilities effective interest rates debt instruments millions chf effective interest rate european medium term note programme bonds due october principal million euros bonds due august principal million pounds sterling fully redeemed october principal million us dollars swiss franc bonds rodeo due march principal billion swiss francs us dollar bonds chameleon due july principal million us dollars zero coupon us dollar exchangeable notes lyons v fully redeemed july principal million us dollars genentech senior notes senior notes due july principal million us dollars senior notes due july principal billion us dollars senior notes due july principal million us dollars genentech commercial paper notes due various dates january principal million us dollars japanese yen convertible bonds issued chugai series chugai pharmaceutical unsecured convertible bonds due september principal amount million japanese yen billion japanese yen total debt instruments unamortised discount included carrying value debt instruments millions chf sterling bonds zero coupon us dollar exchangeable notes total unamortised discount fair value option group applied fair value option three outstanding debt instruments group applying fair value hedge accounting past debt instruments european medium term note programme euro bonds chameleon us dollar bonds rodeo swiss franc bonds fairvalue option treatment based elimination accounting mismatch recognised hedging swaps reported fair value hedged bonds reported amortised cost difference carrying value principal amount debt instruments totals million swissfrancs million swiss francs finance report roche group notes roche group consolidated financial statements issuance new debt instruments genentech commercial paper programin october genentech established commercial paper program issue billion us dollars unsecured commercial paper notes maturities theprogram generally vary overnight five weeks exceed days december unsecured commercial paper notes principal amount million us dollars interest rate outstanding cash proceeds issue equivalent million swiss francs genentech intends touse proceeds general corporate purposes repayments redemptions conversions debt instruments conversion redemption lyons v us dollar exchangeable notes june group announced would exercise option call notes redemption july original issue amount plus accrued original issue discount oid period july notes principal amount million us dollars converted million nonvoting equity securities remaining notes redeemed cash july total million swiss francs recorded equity consists million swiss francs cash used purchase nonvoting equity securities used conversion redemption less million swiss francs carrying value converted bonds related tax effects million swiss francs gain loss recorded income statement upon conversion redemption redemption european medium term note programme us dollar bonds due date october group redeemed bonds principal value million us dollars original issue amount plus accrued original issue discount oid cash outflow million swiss francs gain loss recorded income statement upon redemption partial conversion series chugai pharmaceutical unsecured convertible bonds bonds face value billion japanese yen million swiss francs converted shares chugai groups percentage ownership chugai unaffected conversion group bonds convertible chugai shares mirror chugai outstanding third parties gain loss recorded income statement upon partial conversion repayments redemptions conversions debt instruments partial conversion lyons v us dollar exchangeable notes notes carrying value million us dollars million swiss francs converted million nonvoting equity securities notes called conversion represented number notes outstanding start year total million swiss francs recorded equity consisted million swiss francs cash used purchase nonvoting equity securities used conversion less million swiss francs carrying value converted bonds related tax effects million swiss francs gain orloss recorded income statement upon partial conversion partial conversion series chugai pharmaceutical unsecured convertible bondsduring bonds face value billion japanese yen million swiss francs converted shares chugai groups percentage ownership chugai unaffected conversion group bonds convertible chugai shares mirror chugai outstanding third parties gain loss recorded income statement upon partial conversion cash outflows repayments redemptions conversions debt instruments millions chf lyons v us dollar exchangeable notes european medium term note programme us dollar bonds total cash outflows repayments redemptions year finance report roche group notes roche group consolidated financial statements terms outstanding convertible debt instruments series chugai pharmaceutical unsecured convertible bonds bond jpy par value isconvertible shares chugai conversion option bondholder may made time september bonds redeemable maturity september issue price bonds outstanding december converted would require thousand chugai shares meet obligation groups percentage ownership chugai would affected conversion asthe group bonds convertible chugai shares mirror chugai outstanding third parties equity attributable roche shareholders changes equity attributable roche shareholders millions chf share equity retained fair value hedging translation year ended december capital instruments earnings reserve reserve reserve total january availableforsale investments valuation gains losses taken equity transferred income statement sale impairment cash flow hedges gains losses taken equity transferred income statement transferred initial balance sheet carrying value hedged items exchange differences translation foreign operations defined benefit plans actuarial gains losses limit asset recognition income taxes items taken directly transferred equity minority interests net income recognised directly equity net income recognised income statement total recognised income expense dividends paid transactions equity instruments equity compensation plans genentech chugai share repurchases convertible debt instruments changes minority interests december finance report roche group notes roche group consolidated financial statements equity share instru retained fair value hedging translation year ended december capital ments earnings reserve reserve reserve total january availableforsale investments valuation gains losses taken equity transferred income statement sale impairment cash flow hedges gains losses taken equity transferred income statementa transferred initial balance sheet carrying value hedged items exchange differences translation foreign operations defined benefit plans actuarial gains losses limit asset recognition income taxes items taken directly transferred equity minority interests net income recognised directly equity net income recognised income statement total recognised income expense dividends paid transactions equity instruments equity compensation plans genentech chugai share repurchases convertible debt instruments changes minority interests december amounts transferred income statement losses million swiss francs reported royalties operating income gains million swiss francs financial income share capital december authorised issued share capital roche holding ltd groups parent company consisted shares nominal value swiss franc preceding year shares bearer shares group maintain register shareholders based information supplied group shareholder group pooled voting rights owns issued shares described note based information supplied group novartis international ltd basel affiliates participation issued shares finance report roche group notes roche group consolidated financial statements nonvoting equity securitiesgenussscheine december nonvoting equity securities authorised issue preceding year swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates accordance law articles incorporation roche holding ltd company entitled times exchange thenonvoting equity securities shares participation certificates dividends march shareholders approved distribution dividend chf per share nonvoting equity security chf respect business year distribution holders outstanding shares nonvoting equity securities totalled million swiss francs million swiss francs recorded retained earnings board directors proposed dividends business year swiss francs per share nonvoting equity security subject approval attheannual general meeting march equity instruments holdings equity instruments equivalent number nonvoting equity securities december december millions millions nonvoting equity securities low exercise price options derivative instruments total equity instruments equity instruments recorded within equity original purchase cost details equity instruments held december shown table fair values disclosed information purposes equity instruments december supplementary information equivalent number nonvoting equity securities strike price market value millions maturity chf millions chf nonvoting equity securities na na low exercise price options sep derivative instruments feb feb total nonvoting equity securities low exercise price options mainly held potential conversion obligations may arise groups convertible debt instruments following conversion redemption lyons v us dollar exchangeable notes see note group reduced holdings equity instruments year groups potential obligations employees roche option plan roche stocksettled stock appreciation rights see note covered remaining equity instruments mainly consist call options exercisable time maturity net cash inflow transactions equity instruments million swiss francs net cash inflow million swiss francs mainly arose reduction equity instrument holdings following conversion redemption lyons v notes group holds none shares finance report roche group notes roche group consolidated financial statements reserves fair value reserve fair value reserve represents cumulative net change fair value available forsale financial assets asset sold impaired otherwise disposed hedging reserve hedging reserve represents effective portion cumulative net change fair value cash flow hedging instruments related hedged transactions yet occurred translation reserve translation reserve represents cumulative currency translation differences relating consolidation group companies use functional currencies swiss francs earnings per share nonvoting equity security basic earnings per share nonvoting equity security calculation basic earnings per share nonvoting equity security number shares non voting equity securities reduced weighted average number nonvoting equity securities held group period basic earnings per share nonvoting equity security continuing businesses group net income attributable roche shareholders millions chf number shares millions number nonvoting equity securities millions weighted average number nonvoting equity securities held millions weighted average number shares nonvoting equity securities issue millions basic earnings per share nonvoting equity security chf diluted earnings per share nonvoting equity security calculation diluted earnings per share nonvoting equity security net income weighted average number shares nonvoting equity securities outstanding adjusted effects dilutive potential shares nonvoting equity securities potential dilutive effects arise convertible debt instruments employee stock option plans outstanding convertible debt instruments converted would lead reduction interest expense increase number shares may net dilutive effect earnings per share exercise outstanding vested employee stock options would dilutive effect exercise outstanding vested genentech employee stock options would dilutive effect net income genentech positive diluted earnings per share nonvoting equity security reflects potential impacts dilutive effects earnings per share figures finance report roche group notes roche group consolidated financial statements diluted earnings per share nonvoting equity security continuing businesses group net income attributable roche shareholders millions chf elimination interest expense net tax convertible debt instruments dilutive millions chf increase minority share group net income net tax assuming outstanding genentech stock options exercised millions chf net income used calculate diluted earnings per share millions chf weighted average number shares nonvoting equity securities issue millions adjustment assumed conversion convertible debt instruments dilutive millions adjustment assumed exercise equity compensation plans dilutive millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions diluted earnings per share nonvoting equity security chf minority interests changes equity attributable minority interests millions chf january net income recognised directly equity net income recognised income statement genentech chugai minority interests total net income recognised income statement total recognised income expense dividends paid minority shareholders equity compensation plans genentech chugai share repurchases convertible debt instruments changes minority interests december genentech chugai minority interests total minority interests finance report roche group notes roche group consolidated financial statements cash flow statement cash flows operating activities cash flows operating activities arise groups primary activities pharmaceuticals diagnostics businesses calculated indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation impairment order derive cash generated operations operating cash flows shown cash flow statement operating cash flows also include income taxes paid activities includingforexample taxes paid income bond conversion redemption cash generated operations millions chf net income add back nonoperating income expense associated companies financial income financing costs income taxes discontinued businesses operating profit depreciation property plant equipment amortisation intangible assets impairment intangible assets impairment property plant equipment operating expenses defined benefit postemployment plans operating expenses equitysettled equity compensation plans adjustments cash generated operations cash flows investing activities cash flows investing activities principally arising groups investments property plant equipment intangible assets acquisition divestment subsidiaries associated companies businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects business combinations divestments well cash generated groups investments interest dividends received millions chf interest received dividends received total finance report roche group notes roche group consolidated financial statements cash flows financing activities cash flows financing activities primarily proceeds issue repayment groups equity debt instruments also include interest payments dividend payments instruments cashflows shortterm financing including finance leases also included cash flows indicate groups transactions providers equity debt financing cash flows shortterm borrowings shown net movement consist large number transactions short maturity interest dividends paid millions chf interest paid dividends paid total significant noncash transactions increase property plant equipment million swiss francs million swiss francs recorded genentech leasing arrangements see note corresponding increase long term debt risk management group risk management risk management fundamental element groups business practice levels encompasses different types risks group level risk management integral part business planning controlling processes material risks monitored regularly discussed corporate executive committee audit committee board directors overall group risk management process includes performance risk assessment described detail business report page financial risk management specifically described detail financial risk management group exposed various financial risks arising underlying operations corporate finance activities groups financial risk exposures predominantly related changes foreign exchange rates interest rates equity prices well creditworthiness solvency groups counterparties financial risk management within group governed policies reviewed boards directors roche genentech chugai appropriate areas statutory responsibility policies cover credit risk liquidity risk market risk policies provide guidance risk limits type authorised financial instruments monitoring procedures general principle policies prohibit use derivative financial instruments speculative trading purposes policy implementation daytoday risk management carried relevant treasury functions regular reporting risks performed relevant accounting controlling functions within roche genentech chugai finance report roche group notes roche group consolidated financial statements carrying amount fair value financial assets asset class millions chf carrying value asset classes fvtpla fvtpla available desig held held loans fair line items notes forsale cash nated trading maturity receivables total value year ended december accounts receivable accrued interest income marketable securities money market instruments time accounts months bonds debentures shares investments cash cash equivalents derivative financial instruments availableforsale investments heldtomaturity investments loans receivable longterm trade receivables financial current assets restricted cash longterm assets total fairvaluethroughprofitorloss finance report roche group notes roche group consolidated financial statements carrying value asset classes fvtpla fvtpla available desig held held loans fair line items notes forsale cash nated trading maturity receivables total value year ended december accounts receivable accrued interest income marketable securities money market instruments time accounts months bonds debentures shares investments cash cash equivalents derivative financial instruments availableforsale investments heldtomaturity investments loans receivable longterm trade receivables financial current assets restricted cash longterm assets total fairvaluethroughprofitorloss credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group objective managing counterparty credit risk prevent losses liquid funds deposited invested counterparties maximum exposure credit risk resulting financial activities without considering netting agreements without taking account collateral held credit enhancements equal carrying amount groups financial assets finance report roche group notes roche group consolidated financial statements trade receivables subject policy active credit risk management focuses assessment country risk credit availability ongoing credit evaluation account monitoring procedures objective management trade receivables sustain growth profitability group optimising asset utilisation whilst maintaining risks acceptable level except noted significant concentration counterparty credit risk due groups large number customers wide geographical spread risk limits exposures continuously monitored country nature counterparties additionally group obtains credit insurance similar enhancements appropriate protect collection trade receivables december collateral held loansand receivables none december groups combined trade accounts receivable balance three us national wholesale distributors amerisourcebergen corp cardinal health inc mckesson corp equivalent billion swiss francs representing groups consolidated trade accounts receivable billion swiss francs representing nature geographical location trade receivables counterparties millions chf whole whole salers salers regions total public distributors private total public distributors private switzerland european union rest europe north america latin america japan rest asia africa australia oceania total loans receivables cash marketable securities subject policy restricting exposures highquality counterparties setting defined limits individual counterparties limits counterparty credit ratings reviewed regularly investments marketable securities entered basis guidelines regard liquidity quality maximum amount general rule group invests high quality securities adequate liquidity cash shortterm time deposits subject rules limit groups exposure individual financial institutions group signs netting agreements isda international swaps derivatives association master agreement respective counterparties order control exposures derivative positions overdue assets financial assets past due impaired total billion swiss francs billion swiss francs analysis overdue impaired financial assets class millions chf total amount overdue month months months months year year ended december loans receivables year ended december loans receivables december financial assets whose terms renegotiated none finance report roche group notes roche group consolidated financial statements liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time group liquidity reported senior management monthly basis members group enjoy strong credit quality rated least one major credit rating agency ratings permit roche genentech chugai efficient access international capital markets event major financing requirements addition group unused committed credit lines various financial institutions totalling billion swiss francs unused committed credit lines billion swiss francs contractual maturity analysis financial liabilities millions chf total months months months years years years years years year ended december total debta trade payables accruals derivative financial instruments liabilities current noncurrent total financial liabilities year ended december total debta trade payables accruals derivative financial instruments liabilities current noncurrent total financial liabilities total debt table shows undiscounted cash flows whereas carrying value consolidated balance sheet reflects discounted cash flows market risk market risk arises changing market prices groups financial assets financial liabilities market risk may affect group financial result value group equity group uses valueatrisk var measure impact market risk financial instruments roche defined var limits manage market risk var data reported monthly basis indicate value range within given financial instrument fluctuate preset probability result movements market prices var statistical measure implicitly assumes value changes recent past indicative value changes future var figures represent actual expected losses possible worstcase losses stated period also var consider effects favourable market movements var figures calculated using historical simulation approach scenario financial instruments fully valued total change value earnings determined var calculations based confidence level holding period trading days past years holding period reflectsthe time required change corresponding risk exposure deemed appropriate longer holding periods increase probability higher value changes lead increased var figures finance report roche group notes roche group consolidated financial statements market risk financial instruments millions chf december december var foreign exchange component var interest rate component var price component diversification var total market risk end total var financial assets liabilities million swiss francs million swiss francs foreign exchange var increased mainly due higher hedging levels nonus dollar cash flows future royalty income next five years genentech lower contribution interest rate component caused ageing fixedterm liabilities price risk arises mainly movements prices equity securities group held equity securities market valueofbillion swiss francs billion swiss francs number includes holdings biotechnology companies acquired context licensing transactions scientific collaborations lower holdings equity securities resulted lower var price risk foreign exchange risk group operates across world exposed movements foreign currencies affecting group financial result value groups equity foreign exchange risk arises amount local currency paid received transactions denominated foreign currencies may vary due changes exchange rates transaction exposures foreign currency denominated financial statements groups foreign subsidiaries may vary upon consolidation swiss franc denominated group financial statements translation exposures objective groups foreign exchange risk management activities preserve economic value current future assets minimise volatility groups financial result primary focus groups foreign exchange risk management activities hedging transaction exposures arising foreign currency flows monetary positions held foreign currencies group currently hedge translation exposures using financial instruments group monitors transaction exposures daily basis net foreign exchange result corresponding var parameters reported monthly basis group uses forward contracts foreign exchange options crosscurrency swaps hedge transaction exposures application instruments intends continuously lock favourable developments foreign exchange rates thereby reducing exposure potential future movements rates interest rate risk interest rate risk arises movements interest rates could affect group financial result value group equity changes interest rates may cause variations interest income expense addition may affect market value certain financial assets liabilities hedging instruments primary objective groups interest rate management protect net interest result interest rate exposures corresponding var parameters reported monthly basis group uses forward contracts options swaps hedge interest rate exposures depending interest rate environment major currencies group use instruments generate appropriate mix fixed floating rate exposures finance report roche group notes roche group consolidated financial statements price risk price risk arises mainly movements prices equity securities held roche genentech chugai group held equity securities market value billion swiss francs billion swiss francs amount includes holdings biotechnology companies acquired context licensing transactions scientific collaborations due nature business biotechnology companies exposed greater equity volatilities general stock market fluctuations group manages price risk placing limits individual total equity investments limits defined percentage total liquid funds absolute number individual equity investments equity price risk reported var figure monthly basis senior management impairment financial assets impairments shares triggered significant prolonged price decline cost value impairments debt securities recorded due significant financial difficulties issuers impairment losses asset classesin millions chf loans receivables availableforsale financial assets shares investments debt securities total impairment losses capital group defines capital manages groups total equity including minority interests groups objectives managing capital safeguard groups ability continue going concern continue provide benefits patients returns investors provide adequate return investors based level risk undertaken available necessary financial resources allow group invest areas may deliver future benefits patients returns investors maintain sufficient financial resources mitigate risks unforeseen events capital monitored basis equity ratio calculated equity including minority interests percentage total assets reported senior management part groups regular internal management reporting groups capital equity ratio shown table capital millions chf capital reserves attributable roche shareholders equity attributable minority interests total equity total assets equity ratio group subject regulatory capital adequacy requirements known financial services industry group majority shareholdings genentech see note chugai see note genentech chugai public companies objectives policies processes managing capital aredetermined local management finance report roche group notes roche group consolidated financial statements related parties controlling shareholders share capital roche holding ltd groups parent company consists bearer shares based information supplied shareholder group pooled voting rights comprising ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri mscatherine oeri ms beatrice oeri ms maja oeri group holds shares preceding year represents issued shares figure include shares without pooled voting rights held outside group individual members group mr andr hoffmann dr andreas oeri members board directors roche holding ltd capacity received annual remuneration swiss francs since february mr hoffmann vicechairman board directors received swiss francs capacity swiss francs dr oeri chairman corporate governance sustainability committee received swiss francs time expenses capacity swiss francs transactions group individual members shareholder group subsidiaries associated companies listing major group subsidiaries associated companies included note transactions parent company subsidiaries subsidiaries eliminated consolidation significant transactions group associated companies key management personnel members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees total remuneration board directors totalled million swiss francs million swiss francs members corporate executive committee roche holding ltd receive remuneration consists annual salary bonus expense allowance group pays social insurance contributions respect remuneration pays contributions pension postemployment benefit plans members ofthe corporate executive committee members corporate executive committee also participate certain equity compensation plans described terms vesting conditions fair value awards disclosed note remuneration members corporate executive committee millions chf salaries including bonuses expenses social security costs pensions postemployment benefits equity compensation plans employee benefits total roche longterm members corporate executive committee granted stock settled stock appreciation rights ssars roche option plan rop awards ssars rop awards roche connect contributions paid group respect members corporate executive committee totalled million swiss francs million swiss francs roche performance share plan members corporate executive committee targeted awards cycle awards cycle award result inbetween zero two nonvoting equity securities depending upon achievement performance targets finance report roche group notes roche group consolidated financial statements transactions former members corporate executive committee mr heino von prondzynski stepped corporate executive committee december assisted transition successor resigned roche effective december received bonus million swiss francs respect services rendered additionally received total non voting equity securities based prorated roche performance share plan awards total remuneration million swiss francs pensions totalling million swiss francs million swiss francs paid group two former corporate executive committee members detailed disclosures regarding executive remuneration required swiss law included financial statements roche holding ltd basel pages postemployment benefit plans transactions group various postemployment defined benefit plans employees thegroup described note subsequent events january group announced signed agreement acquire controlling interest ventana medical systems inc ventana details given note significant events balance sheet date subsidiaries associated companies listed companies share capital equity interest country company city switzerland roche holding ltd basel chf stock exchange swx zurich valor share valor genussscheine isin share ch isin genussscheinech market capitalisation chf basilea pharmaceutica ltd basel chf stock exchange swx zurich valor isin ch market capitalisation chf united states genentech inc south san francisco usd stock exchange new york incorporated delaware isin us market capitalisation usd japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo isin jp market capitalisation jpy nonlisted companies share capital equity interest country company city argentina productos roche sa qumica e industrial buenos aires ars australia roche diagnostics australia pty limited castle hill aud roche products pty limited dee aud austria roche austria gmbh vienna eur roche diagnostics gmbh vienna eur roche diagnostics graz gmbh graz eur belgium nv roche sa brussels eur roche diagnostics belgium sa brussels eur finance report roche group notes roche group consolidated financial statements share capital equity interest country company city bermuda canadian pharmholding ltd hamilton usd chemical manufacturing trading company limited hamilton usd corange international ltd hamilton usd corange ltd hamilton usd roche financial investments ltd hamilton usd roche financial services ltd hamilton usd roche interfinance ltd hamilton usd roche international ltd hamilton usd roche intertrade ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd brazil produtos roche qumicos e farmacuticos sa paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd st john cad chile roche chile limitada santiago de chile clp china roche diagnostics hong kong limited hong kong hkd roche diagnostics shanghai limited shanghai usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia productos roche sa bogot cop costa rica roche servicios sa heredia usd croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche hvidovre dkk roche bio denmark copenhagen dkk roche diagnostics hvidovre dkk dominican productos roche dominicana sa santo domingo dop republic ecuador roche ecuador sa quito usd el salvador productos roche el salvador sa san salvador svc estonia roche eesti tallinn eek finland roche diagnostics oy espoo eur roche oy espoo eur france cenexi sas fontenay sous bois eur roche diagnostics sa meylan eur roche sas neuillysurseine eur germany galenus mannheim gmbh mannheim eur roche beteiligungs gmbh grenzachwyhlen eur roche deutschland holding gmbh grenzachwyhlen dem roche diagnostics gmbh mannheim eur roche kulmbach gmbh kulmbach eur roche pharma ag grenzachwyhlen eur greece roche hellas sa athens eur roche diagnostics hellas sa athens eur guatemala productos roche guatemala sa guatemala gtq honduras productos roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diagnostics india pvt ltd mumbai inr roche scientific company india pvt ltd mumbai inr finance report roche group notes roche group consolidated financial statements share capital equity interest country company city indonesia pt roche indonesia jakarta idr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur italy roche diagnostics spa milan eur roche spa milan eur japan roche diagnostics kk tokyo jpy latvia roche latvija sia riga lvl lithuania uab roche lietuva vilnius lit luxembourg pharminvest sa luxembourg eur malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostics malaysia sdn bhd kuala lumpur myr mexico grupo roche syntex de mxico sa de cv mexico city mxn lakeside de mxico sa de cv mexico city mxn productos roche sa de cv mexico city mxn syntex sa de cv mexico city mxn morocco roche sa casablanca mad netherlands roche diagnostics nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholding bv woerden eur new zealand roche diagnostics new zealand pty ltd auckland nzd roche products new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio norway roche diagnostics norge oslo nok roche norge oslo nok pakistan roche pakistan ltd karachi pkr panama productos roche interamericana sa panama city usd productos roche panam sa panama city pab syntex corporation panama city usd syntex puerto rico inc panama city usd technical development corp panama city chf peru productos roche qumica farmacutica sa lima pen philippines roche philippines inc makati php poland roche diagnostics polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda lindaavelha eur puerto rico corange int limited puerto rico branch ponce usd romania roche romania srl bucharest ron russia roche moscow ltd moscow rub serbia roche doo beograd belgrade eur singapore roche diagnostics asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd slovakia roche slovensko sro bratislava skk slovenia roche doo pharmaceutical company ljubljana eur south africa roche products proprietary limited johannesburg zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain andreu roche sa madrid eur roche diagnostics sl barcelona eur roche farma sa madrid eur syntex roche sa madrid eur finance report roche group notes roche group consolidated financial statements share capital equity interest country company city sweden roche ab stockholm sek roche diagnostics scandinavia ab bromma sek switzerland disetronic handels ag burgdorf chf disetronic holding ag burgdorf chf disetronic licensing ag burgdorf chf disetronic medical systems ag burgdorf chf f hoffmannla roche ltd basel chf glycart biotechnology ltd schlieren chf hoffmannla roche ltd basel chf imib institute medical informatics biostatistics ltd basel chf rabbitair ltd zurichkloten chf roche capital market ltd basel chf roche diagnostics switzerland ltd rotkreuz chf roche diagnostics ag rotkreuz chf roche diagnostics international ltd steinhausen chf roche finance ltd basel chf roche pharma switzerland ltd reinach chf syntex corporation basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostics thailand limited bangkok thb roche thailand limited bangkok thb turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try united kingdom roche diagnostics ltd lewes gbp roche holding uk limited welwyn garden city gbp roche products limited welwyn garden city gbp roche registration limited welwyn garden city gbp united states life sciences corporation branford usd bioveris corporation gaithersburg usd disetronic medical systems inc st paul usd hoffmannla roche inc nutley usd idaho technology inc salt lake city usd igen international inc wilmington usd roche carolina inc florence usd roche colorado corporation boulder usd roche diagnostics corporation indianapolis usd roche diagnostics operations inc indianapolis usd roche finance america inc little falls usd roche finance usa inc little falls usd roche holdings inc wilmington usd roche laboratories inc nutley usd roche molecular systems inc pleasanton usd roche nimblegen inc wilmington usd roche palo alto llc palo alto usd therapeutic human polyclonals inc palo alto usd uruguay roche international ltd montevideo branch montevideo uyu venezuela productos roche sa caracas veb share capital less local currency units finance report report roche management report roche management internal control financial reporting board directors management roche holding ltd responsible establishing maintaining adequate control financial reporting internal control system designed provide reasonable assurance reliability financial reporting preparation fair presentation consolidated financial statements accordance international financial reporting standards internal control systems matter well designed inherent limitations therefore even systems determined effective may prevent detect misstatements provide reasonable assurance respect financial statement preparation presentation also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate management assessed effectiveness system internal control financial reporting december based criteria effective internal control financial reporting described ininternal control integrated framework issued committee sponsoring organisations treadway commission coso based assessment management concluded system internal control financial reporting effective december group auditors kpmg klynveld peat marwick goerdeler sa audited consolidated financial statements roche holding ltd year ended december accordance swiss auditing standards international standards auditing isa also issued report effectiveness groups system internal control financial reporting report set franz b humer erich hunziker chairman board directors chief financial officer deputy head chief executive officer corporate executive committee basel january finance report report group auditors report group auditors annual general meeting roche holding ltd basel group auditors audited consolidated financial statements income statement balance sheet cashflow statement statement recognised income expense statement changes equity notes pages roche holding ltd year ended december consolidated financial statements responsibility board directors responsibility toexpress opinion consolidated financial statements based audit confirm meet legal requirements concerning professional qualification independence audit conducted accordance swiss auditing standards international standards auditing isa require audit planned performed obtain reasonable assurance whether consolidated financial statements free material misstatement examined test basis evidence supporting amounts disclosures consolidated financial statements also assessed accounting principles used significant estimates made overall consolidated financial statement presentation believe audit provides reasonable basis opinion opinion consolidated financial statements give true fair view financial position results operations cash flows accordance international financial reporting standards ifrs comply swiss law recommend consolidated financial statements submitted approved kpmg klynveld peat marwick goerdeler sa john morris erik fj willems auditor charge basel january finance report report group auditors internal control financial reporting report group auditors annual general meeting roche holding ltd basel examined roche groups system internal control financial reporting december based criteria established internal control integrated frameworkissued committee sponsoring organisations treadway commission coso board directors management roche holding ltd responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying consolidated financial statements responsibility express opinion companys internal control financial reporting based examination entitys internal control financial reporting process effected entitys board directors management personnel designed provide reasonable assurance regarding reliability financial statements prepared accordance international financial reporting standards ifrs includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets entity provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance applicable financial reporting framework provide reasonable assurance regarding prevention timely detection unauthorised acquisition use disposition entitys assets could material effect entitys financial statements conducted examination accordance international standard assurance engagements isae standard requires plan perform examination obtain reasonable assurance whether effective internal control financial reporting maintained material aspects examination included obtaining understanding internal control financial reporting testing evaluating design operating effectiveness internal control performing procedures considered necessary circumstances believe examination provides reasonable basis opinion inherent limitations internal control financial reporting including possibility management override controls misstatements due error fraud may occur detected also projections evaluation internal control financial reporting future periods subject risk internal control may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion roche group maintained material respects effective internal control financial reporting december based criteria established internal control integrated frameworkissued committee sponsoring organisations treadway commission coso also audited accordance swiss auditing standards international standards auditing isa consolidated financial statements roche holding ltd year ended december report dated january expressed unqualified opinion kpmg klynveld peat marwick goerdeler sa john morris erik fj willems auditor charge basel january finance report multiyear overview statistics reported statement income millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable minority interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income equity attributable roche shareholders research development sales current ratio equity minority interests total assets sales per employee thousands chf data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf b earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf b cash warrants addition dividend chf information table stated reported changes accounting policies arising changes international financial reporting standards stock split applied retrospectively finance report roche group multiyear overview c c assuming centenary warrants held final exercise date b dividend include special dividend relating spinoff fragrances flavours division c dividend proposed board directors finance report roche group multiyear overview sales division millions chf pharmaceuticals diagnostics consumer health otc vitamins fine chemicals total sales geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total additions property plant equipment division millions chf pharmaceuticals diagnostics consumer health otc vitamins fine chemicals corporate total additions property plant equipment geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total european union information based members eu december comparative information restated include new eu members whole fiveyear period finance report supplementary net income eps information groups basic diluted earnings per share information given note consolidated financial statements pages supplementary eps information given net income exceptional items also core net income additionally excludes amortisation intangible assets related impacts income taxes minority interests profit continuing businesses exceptional items core net income millions chf year ended december profit continuing businesses major legal cases income taxes profit continuing businesses exceptional items minority interests profit continuing businesses net income attributable roche shareholders continuing businesses exceptional items amortisation impairment intangible assets income taxes minority interest core net income eps continuing businesses exceptional items core eps eps continuing businesses exceptional items core eps year ended december net income attributable roche shareholders millions chf elimination interest expense net tax convertible debt instruments dilutive increase minority share net income net tax assuming outstanding genentech chugai stock options exercised net income used calculate diluted earnings per share per share information millions shares nonvoting equity securities weighted average number shares nonvoting equity securities issue adjustment assumed conversion convertible debt instruments dilutive adjustment assumed exercise equity compensation plans dilutive weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share earnings per share dilutedchf finance report roche securities price development share chf roche share swiss market index rebased price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased price development american depositary receipt adr usd roche adr sp index rebased two roche american depositary receipts adrs equivalent one nonvoting equity securitygenussschein adrs traded united states overthecounter market since july information tables restated stock split roche shares nonvoting equity securities genussscheine effective may change ratio adrs effective january finance report roche group roche securities number shares nonvoting equity securitiesa number shares nominal value chf number nonvoting equity securities genussscheine nominal value total data per share nonvoting equity security chf net income equity dividend c stock price shareb high low yearend stock price nonvoting equity security genussscheinb high low yearend market capitalisation millions chf yearend key ratios yearend net income equity dividend yield shares dividend yield nonvoting equity securities genussscheinein priceearnings shares priceearnings nonvoting equity securities genussscheine nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices c dividend proposed board directors ticker symbols share nonvoting equity security american depositary receipt reuters ros rogvx rhhbypk bloomberg ro sw rog vx rhhby us swx swiss exchange ro rog finance report roche holding ltd basel financial statements income statement millions chf income income participations interest income loans group companies interest investment income income total income expenses financial expenses administration expenses expenses total expenses profit year taxes taxes net profit year finance report roche holding ltd basel financial statements balance sheet december millions chf noncurrent assets participations longterm loans group companies total noncurrent assets current assets accounts receivable group companies accounts receivable marketable securities liquid funds total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm general legal reserve free reserve special reserve available earnings balance brought forward previous year net profit year total equity noncurrent liabilities provisions total noncurrent liabilities current liabilities accounts payable group companies unrealised foreign currency gains liabilities total current liabilities total liabilities total equity liabilities pm pro memoria nonvoting equity securities nominal value finance report notes financial statements summary significant accounting policies basis preparation financial statements financial statements roche holding ltd basel prepared accordance provisions swiss law participations major participations company listed note roche group consolidated financial statements valuation methods translation foreign currencies marketable securities reported lower cost market value assets including participations reported cost less appropriate writedowns assets liabilities denominated foreign currencies translated swiss francs using yearend rates exchange except participations translated historical rates transactions year denominated foreign currencies translated exchange rates effective relevant transaction dates resulting exchange gains losses recognised income statement exception unrealised gains deferred taxes tax charge includes corporate income capital taxes equity share capital previous year share capital amounts million swiss francs share capital consists bearer shares nominal value swiss franc included equity nonvoting equity securities genussscheine part share capital confer voting rights however non voting equity security genussscheinconfers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value share capital participation certificates movement recognised amounts millions chf general share legal free special available total capital reserve reserve reserve earnings equity january net income dividends paid transfer free reserve december net income dividends paid transfer free reserve december net income dividends paid transfer free reserve december finance report roche holding ltd basel notes financial statements convertibles options reference made notes roche group consolidated financial statements equity instruments reference made notes roche group consolidated financial statements contingent liabilities guarantees within framework european medium term note emtn programme company issued guarantees favour group companies amounting million swiss francs previous year million swiss francs time preparing balance sheet risks arising contingent liabilities discernible significant shareholders shares company bearer shares reason company keep register shareholders following figures based information shareholders shareholder validation check annual general meeting march information available company previous year shares shareholder group pooled voting rights comprising ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri mscatherine oeri ms beatrice oeri ms maja oeria previous year shares participation novartis international ltd basel including affiliates thereofb information supplied shareholders figure shares include shares without pooled voting rights held outside group individual members group b figures december supplied novartis international ltd basel finance report roche holding ltd basel notes financial statements executive remuneration board directors members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees remuneration members board directors thousands chf compensation annual board committee remuneration members compensation total executive director fb humer nonexecutive directors b gehrig hoffmann p baschera ji bell p brabeckletmathe ljr de vink w frey da julius oeri w ruttenstorfer h teltschik b weder di mauro total nonexecutive directors total remuneration board directors remuneration prof bruno gehrig includes serving independent lead director vicechairman board directors remuneration mr andr hoffmann includes serving vicechairman board directors july prof sir john bell completed oneyear sabbatical leave university oxford roche roche paid personal family expenses prof bell incurred relation stay switzerland including insurance costs expenses totalled swiss francs addition roche paid swiss francs retirement policy prof bell prof horst teltschik received honoraria including expenses amounting euros swiss francs serving boards several roche subsidiaries germany otherwise additional remuneration paid members board directors corporate executive committee members corporate executive committee cec roche holding ltd receive remuneration indirect benefits participate certain equity compensation plans shown table chairman ceo dr franz b humer member board directors corporate executive committee highest total remuneration finance report roche holding ltd basel notes financial statements total remuneration members corporate executive committee thousands chf cec total fb humer annual salary bonus expense allowance pensions postemployment benefits equity compensation plans employee benefits total remuneration received social security costs total annual salarythe annual salary amount dr humer includes swiss francs receives capacity member board directors described employer contribution social security schemes pension plans group pays social insurance contributions respect remuneration pays contributions pension postemployment benefits plans members corporate executive committee owing amendments switzerlands federal occupational old age survivors disability pension act bvg contributions behalf dr humer limited swiss francs due existing contractual obligations dr humer additional provision swiss francs recognised group included amounts shown table equity compensation plansmembers corporate executive committee also participate certain equity compensation plans described terms vesting conditions awards disclosed note consolidated financial statements fair values used consolidated financial statements represent cost company grant date reflect amongst matters observed exercise behaviour exit rate whole population receive initial simulations performance conditions purposes remuneration disclosures fair values calculated based fair value employee receives taking account preliminary assessment completed performance conditions members corporate executive committee granted stocksettled stock appreciation rights ssars individual awards relating shown table fair value awards employee chf francs calculated using blackscholes formula assuming holding maturity deducting average year vesting period members corporate executive committee members senior management participate roche performance share plan psp group three overlapping threeyear psps target awards threeyear cycle defined beginning cycle awards considered form part employees remuneration three equal annual amounts threeyear cycle award result zero two nonvoting equity securities genussscheine depending upon achievement performance targets discretion board directors individual awards relating shown table number awards calculated follows psp preliminary allocation based actual performance period shows two nonvoting equity securities genussscheineper award psp psp one nonvoting equity securities genussscheineper award resulting allocations multiplied nonvoting equity security genussscheineprice december chf give fair value remuneration received employee finance report roche holding ltd basel notes financial statements remuneration equity compensation plans thousands chf roche ssar awards psp awards connect ssar psp psp psp psp total employer ssar fair fair fair contributions number value number number number value value cec total fb humer employee benefits includes tax advisory costs remuneration dr humer dr hunziker mrburns prof knowles serving chugai board directors transactions former members corporate executive committee mr heino von prondzynski stepped corporate executive committee december assisted transition successor resigned roche effective december received abonus thousand swiss francs respect services rendered additionally received total nonvoting equity securities based prorated roche performance share plan awards pensions totalling thousand swiss francs paid group two former corporate executive committee members executive shareholdings board directors directors mr andr hoffmann dr andreas oeri members founders families closely associated belong shareholder group pooled voting rights end group held shares issued shares mr hoffmann serves spokesman shareholder group detailed information group given note addition december nonexecutive members board directors persons closely associated held shares nonvoting equity securities genussscheineas shown table shareholdings members board directors december nonvoting equity securities shares genussscheine fb humer b b gehrig hoffmann c p baschera ji bell p brabeckletmathe ljr de vink w frey da julius oeri c w ruttenstorfer h teltschik b weder di mauro total figure include shares held shareholder group pooled voting rights b equity compensation awards roche option plan ssars roche performance share plan see c mr hoffmann dr oeri hold ubs longshort certificates roche bearer shares ro versus roche nonvoting equity securities rog isin ch mr lodewijk de vink holds roche american depositary receipts adrs rhhby isin us corporate executive committee shareholdings members corporate executive committee persons closely associated held shares nonvoting equity securities genussscheineas shown table finance report roche holding ltd basel notes financial statements shareholdings members corporate executive committee december nonvoting equity securities shares genussscheine fb humer wm burns e hunziker ga keller b jkc knowles schwan total equity compensation awards roche option plan ssars roche performance share plan see b dr kellers close relatives hold roche nonvoting equity securities genussscheine december members corporate executive committee held stocksettled stock appreciation rights ssars first issued roche option plan awards issued shown table option entitles holder purchase one roche nonvoting equity security genussscheine specified strike price terms vesting conditions awards disclosed note consolidated financial statements additional supplementary information remuneration report included business report pages roche option plan ssars awards held december year issue total fb humer wm burns e hunziker ga keller jkc knowles schwan total strike price chf expiry date feb feb feb feb feb december members corporate executive committee held psp awards three psp performance cycles shown table terms vesting conditions awards disclosed note consolidated financial statements additional supplementary information remuneration report pages business report award result zero two nonvoting equity securities genussscheine depending upon achievement performance targets discretion board directors preliminary allocation ratio plan total target number awards cycles december shown table roche performance share plan awards held december psp psp psp fb humer wm burns e hunziker ga keller jkc knowles schwan total awards initially targeted grant date allocation date feb feb feb estimated allocation december total estimated awards december finance report appropriation available earnings proposals annual general meeting chf available earnings net profit year balance brought forward previous year total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf last year transfer free reserve total appropriation available earnings carried forward account finance report report statutory auditors report statutory auditors annual general meeting roche holding ltd basel statutory auditors audited accounting records financial statements income statement balance sheet notes pages roche holding ltd year ended december financial statements responsibility board directors responsibility express opinion financial statements based audit confirm meet legal requirements concerning professional qualification independence audit conducted accordance swiss auditing standards require audit planned performed obtain reasonable assurance whether financial statements free material misstatement examined test basis evidence supporting amounts disclosures thefinancial statements also assessed accounting principles used significant estimates made overall financial statement presentation believe audit provides reasonable basis opinion opinion accounting records financial statements proposed appropriation available earnings comply swiss law companys articles incorporation recommend financial statements submitted approved kpmg klynveld peat marwick goerdeler sa john morris erik fj willems auditor charge basel january finance report published cautionary statement regarding forward fhoffmannla roche ltd looking statements baselswitzerland annual report contains certain forwardlook tel ing statements forwardlooking statements fax may identified words believes expects anticipates projects intends media office seeks estimates future similar expressions corporate communications discussion among things strategy baselswitzerland goals plans intentions various factors may tel cause actual results differ materially future fax reflected forwardlooking statements contained annual report among others investor relations pricing product initiatives competitors baselswitzerland legislative regulatory developments tel economic conditions delay inability fax obtaining regulatory approvals bringing prod ucts market fluctuations currency world wide web exchange rates general financial market condi httpwwwrochecom tions uncertainties discovery develop ment marketing new products new uses order publications existing products including without limitation tel negative results ofclinical trials research projects fax unexpected side effects pipeline marketed emailbaselwebmasterrochecom products increased government pricing pres sures interruptions production loss orinability obtain adequate protection intel lectual property rights litigation loss key executives employeesand adverse publicity news coverage statement regarding earnings per share growth profit forecast inter preted mean roches earnings earnings per share subsequent period necessarily match exceed historical published earnings earnings per share ofroche next annual general meeting march trademarks mentioned enjoy legal protection roche annual report published german english printed nonchlorine bleached fsccertified paper roche annual report issued f hoffmannla roche ltd basel corporate communications finance report